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General introduction
1. EyE DISEASE AnD VISuAl ImPAIrmEnt
Eye disease and its complications are a significant health problem worldwide that im-
pact greatly on quality of life. Visual impairment, the main consequence of eye disease, 
is one of the most common and feared disabilities among human beings [1]. The World 
Health Organisation (WHO), based on the International Classification of Diseases (ICD-
10) (table 1), estimates that 285 million individuals are visually impaired worldwide of 
whom 39 million are blind [2-3]. Moreover, due to demographic trends such as increased 
longevity and population growth, the prevalence of visual impairment will most likely 
increase in the upcoming decades [1, 4-5].
The prevalence of visual impairment differs geographically with the developing world 
hit hardest. Ninety percent of visually impaired individuals live in low-resource countries 
and the relation between lower socioeconomic status and higher rates of visual dis-
ability is unequivocal [2, 6]. In sub-Saharan Africa, an estimated 26 million individuals 
live with visual impairment of whom 5.9 million individuals are classified blind [2]. For 
South Africa, the estimated national prevalence of visual impairment in individuals aged 
50 years and above is 13.8%, but regional prevalence rates differ extensively [7]. For 
example, this reported national prevalence is much higher compared to a population 
based study from Cape Town in the same age group that reported a prevalence of 4.9%. 
The difference in prevalence observed in these studies suggests that visual impairment 
is a significant larger problem in rural compared to urban settings [8]. Lower socioeco-
nomic status of individuals living in rural settings is most likely one of the main reasons 
for this difference, but other causes including different availability and accessibility 
of ophthalmic services, which are far more available and accessible in urban settings 
compared to rural settings may also play a role [6, 9-10].
Visually impaired individuals – as well as their families and communities – face seri-
ous social, educational, employment and economic challenges and visual impairment 
table 1. Classification of visual impairment and blindness according to the International Classification of 
Diseases [3].
category
Presenting distance visual acuity
Worse than Equal to or better than
0 Mild or no visual impairment 6/18
1 Moderate visual impairment 6/18 6/60
2 Severe visual impairment 6/60 3/60
3 Blindness 3/60 1/60a
4 Blindness 1/60a Light perception
5 Blindness No light perception
9 Undetermined or unspecified
aor counts fingers at 1 meter.
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impacts substantially on the quality of life and increases the risk of death [10-12]. On a 
larger scale, visual impairment and blindness causes a considerable economic burden 
for the society and consequently put a major burden on healthcare resources, especially 
in developing countries where resources are already limited [13]. As 80% of all causes of 
visual impairment are preventable or curable if recognised early and managed promptly, 
improvement of eye care and prevention of visual impairment should be set a national 
health priority by governments, especially in low-resource countries where the burden 
of visual disability is disproportionally high [2, 6].
Globally, the main causes of visual impairment and blindness are uncorrected refrac-
tive errors and cataracts [2]. However, the spectrum of eye disease causing visual impair-
ment and blindness differs geographically and is related to regional differences in human 
immunodeficiency virus (HIV) prevalence [14-15]. For sub-Saharan African countries, the 
coinciding high HIV prevalence contributes not only to the burden of visual impairment, 
but also increases the role of serious and sight-threatening eye infections [16-20].
2. InfEctIOuS DISEASES Of tHE EyE
The human eye is the complex organ of vision that lies within the bony orbit of the skull. 
It contains three compartments: (1) the anterior chamber, (2) the posterior chamber and 
(3) the vitreous cavity. The eyeball consists of three concentric layers: (1) the outermost 
layer that consists of the clear cornea anteriorly and the opaque sclera posteriorly, (2) 
the middle highly vascular layer the uvea, which consists of the choroid, ciliary body and 
iris and (3) the innermost photosensitive layer the retina [21]. The eye is well protected 
against infections by a combination of mechanical, anatomical and immunological 
defence mechanisms [22]. Nonetheless, eye infections remain one of the most common 
diseases in ophthalmology, with conjunctivitis, keratitis and uveitis as the most com-
mon infections of the eye (figure 1) [14, 22-27].
Infectious conjunctivitis (‘red eye’) is the inflammatory process of the conjunctiva, the 
thin vascular mucous membrane that consists of the bulbar conjunctiva, attached to 
the sclera and limbus of the cornea and the palpebral conjunctiva, which covers the 
inner surface of the eyelid. Infectious conjunctivitis is characterized by a red eye, cel-
lular infiltration, vascular dilatation and exudation. Acute conjunctivitis is generally 
self-limiting or easily treated, although specific types of conjunctivitis such as infec-
tion with Neisseria gonorrhoea can cause blindness. Infectious keratitis is caused when 
pathogens breach the corneal defence mechanisms and infect the cornea. The cornea, 
a transparent avascular protective membrane, is the most important refractive medium 
of the eye. Corneal infection, and subsequent corneal opacification and scarring, can 
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lead to severe visual impairment and ultimately blindness. This condition, along with 
ocular trauma, are considered the most common cause of visual disability and unilateral 
blindness in sub-Saharan Africa and has been called ‘the silent epidemic’ that warrants 
more attention due to its serious impact on population health [14, 24, 27, 29]. Uveitis 
refers to intraocular infl ammation of the iris, ciliary body, vitreous, retina or choroid. The 
disease is classifi ed by the International Uveitis Study Group into anterior, intermediate 
and posterior uveitis dependent on the segment aff ected or panuveitis when all seg-
ments are infl amed [30]. The visual impact of uveitis depends on the part of the eye 
that is aff ected. In sub-Saharan Africa, uveitis is an important cause of visual impair-
ment and blindness [31]. The aetiology of uveitis is diverse and includes infectious and 
non-infectious causes. Data from the African continent are limited, but suggest that 
pathogens may play an important role in uveitis [31-32].
Ocular infections can be of viral, bacterial, fungal and/or protozoan origin. The likeli-
hood of a specifi c pathogen largely depends on the ocular tissue aff ected (table 2).
2.1 Virus infections of the eye
A genetically diverse group of viruses, including DNA (e.g. Herpesviridae) and RNA (e.g. 
Togaviridae) viruses, is able to cause a wide variety of ocular disease including blephari-
tis, conjunctivitis, keratitis and uveitis [33]. Especially viruses of the Herpesviridae family 
are important pathogens in ophthalmology as they are endemic worldwide and able to 
cause devastating recrudescent ocular disease [33].
Human herpesviruses (HHVs) are members of the Herpesviridae virus family, a large 
family of double-stranded DNA enveloped viruses [34]. Members of this family are 
figure 1. Overview of the anatomic distribution of the most common infectious eye diseases [28].
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classified into three subfamilies based on genomic and biological properties: Alpha-
herpesvirinae, Betaherpesvirinae and Gammaherpesvirinae [35]. Today, nine HHVs have 
been identified: herpes simplex virus 1 (HSV-1), herpes simplex virus 2 (HSV-2), human 
cytomegalovirus (CMV), varicella-zoster virus (VZV), Epstein-Barr virus (EBV), Human 
herpesviruses 6A, 6B, 7, (HHV-6A, HHV-6B and HHV-7) and Kaposi’s sarcoma-associated 
herpesvirus (HHV-8) (table 3) [35].
Whereas primary infection HHVs are commonly asymptomatic, localised or systemic 
disease may occur. Independent of clinical outcome, primary HHV infection will result 
table 2. Distribution of pathogenic microorganisms causing eye infections in sub-Saharan Africa [28].
condition Pathogenic microorganism
conjunctivitis Viruses
No data available on distribution
Bacteria
Chlamydia trachomatis
Neisseria gonorrhoea
Staphylococcus aureus
Streptococcus pneumonia
Staphylococcus albus
Haemophilus influenzae
Keratitis Viruses
Varicella-zoster virus
Herpes simplex virus
Bacteria
Pseudomonas aeruginosa
Escherichia coli
Streptococcus pneumonia
Staphylococcus aureus
Staphylococcus albus
Fungi
Filamentous fungi
Protozoa
Onchocerca volvulus
Acanthamoeba sp.
uveitis Viruses
Herpes simplex virus
Varicella-zoster virus
Cytomegalovirus
Bacteria
Mycobacterium tuberculosis
Treponema pallidum
Protozoa
Toxoplasma gondii
Onchocerca volvulus
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in a lifelong latent infection in neurons (Alphaherpesvirinae) or lymphocytes (Betaher-
pesvirinae and Gammaherpesvirinae) and reactivate from latent infection resulting in a 
symptomatic shedding of the virus or occasionally causing recrudescent disease [33, 
35-37]. The mechanisms that lead to reactivation after asymptomatic latency are largely 
unknown, but immunosenescence due to therapy, disease or ageing play a role [35, 38]. 
High seroprevalence of HHVs is found in humans worldwide, but data from South Africa 
are unavailable [39]. HHVs can cause a wide variety of benign (HHV-6 and 7) and even 
malignant disease (EBV and HHV-8) [33, 36-37]. HSV-1, VZV and CMV are the most com-
mon viral causes of infectious ocular disease worldwide [33, 40].
HSV-1 is transmitted following contact with an active herpetic lesions or an individ-
ual shedding virus asymptomatically [41]. Primary infection occurs usually during early 
childhood via the orofacial route and rarely causes clinical manifestations [41-41]. After 
primary infection, viral latency is established in sensory neurons (i.e. trigeminal and/or 
sacral ganglia) and thereafter HSV-1 may reactivate intermittently to cause asymptom-
atic virus shedding and/or recurrent orofacial and ocular lesions [41-41]. The spectrum 
of eye diseases caused by HSV-1 is diverse and includes blepharitis, conjunctivitis, 
keratitis and uveitis [40, 43]. Recrudescent HSV-1 keratitis, occasionally accompanied 
with corneal opacification and scarring, is the most common eye complication and the 
leading cause of infectious corneal blindness in developed countries (figure 2A) [40, 
44]. Whereas data from South Africa are limited, the impact of the disease is expected to 
be high due to limited access to targeted treatment [44].
VZV infection causes two clinically distinct diseases: varicella (chickenpox) and herpes 
zoster (shingles) [45]. Varicella, result of primary VZV infection, is usually benign and 
occurs predominantly in children. It is characterised by a vesicular exanthema and usu-
table 3. Human herpesviruses [35].
Designation common name Subfamilya Eye manifestationb
Human herpesvirus 1 Herpes simplex virus type 1 α Blepharitis, conjunctivitis, keratitis 
and uveitis
Human herpesvirus 2 Herpes simplex virus type 2 α Keratitis, uveitis and congenital 
cataract
Human herpesvirus 3 Varicella-zoster virus α Herpes zoster ophthalmicus, 
keratitis and uveitis
Human herpesvirus 4 Epstein-Barr virus γ Conjunctivitis, keratitis and uveitis
Human herpesvirus 5 Human cytomegalovirus β Uveitis
Human herpesvirus 6 β Optic neuritis and uveitis
Human herpesvirus 7 β Unknown
Human herpesvirus 8 Kaposi’s sarcoma virus γ Conjunctival Kaposi sarcoma
a α: alphaherpesvirinae; β: betaherpesvirinae and γ: gammaherpesvirinae.
b Most common eye manifestations caused by the respective herpesvirus.
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ally accompanied by fever [45]. Following primary infection, VZV establishes a latent 
infection in both trigeminal and the majority of dorsal root ganglia [46]. After a period of 
latency, reactivation leads to herpes zoster, a painful localised vesicular rash [45]. Reacti-
vation of latent VZV located within the ophthalmic division of the innervating trigeminal 
nerve causes herpes zoster ophthalmicus (HZO) (figure 2b) [47]. HZO represents up to 
a quarter of all cases of herpes zoster [47-48]. If left untreated, eye involvement occurs 
in >50% of HZO patients causing high visual morbidity (figure 2c) [47-49]. HZO-associ-
ated eye diseases include conjunctivitis, scleritis, keratitis, uveitis, optic neuritis, ocular 
cranial-nerve palsies, neuralgia and eyelid deformities [47, 50-51]. The burden of HZO in 
sub-Saharan African countries is high, mainly due to the high HIV prevalence and limited 
access to appropriate anti-viral treatment [52]. HIV-infected individuals have a higher 
risk of developing HZO (>15-times higher) compared to HIV-uninfected individuals and 
have a higher incidence and severity of HZO-associated eye diseases [53-54]. Data from 
South Africa suggest that an increasing proportion of younger HIV-infected patients are 
affected by HZO [52].
A B
C D
figure 2. Clinical presentation of herpesvirus-induced eye diseases. (A) Typical dendritic lesion of the cor-
nea in herpes simplex keratitis. (b) Herpes zoster ophthalmicus of the right side of the face with hyperaemia 
of the conjunctiva and keratouveitis. (c) Anterior uveitis with localized stromal oedema, keratic precipitates 
and cells and flare in the anterior chamber due to infection with varicella-zoster virus. (D) Posterior uveitis 
(retinitis) with retinal bleeding and necrosis due to infection with cytomegalovirus.
17
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CMV infection may occur congenitally causing serious neurological and/or post-
natal disabilities of infected babies [55]. After primary infection, CMV persists in 
hematopoietic progenitor cells and its replication is tightly controlled by the immune 
system [56]. In case of immunodeficiency, CMV viraemia and virus dissemination can 
occur [57]. Disseminated CMV infection may cause full thickness retinitis resulting into 
retinal necrosis and irreversible blindness, but other less severe eye manifestations like 
corneal endotheliitis may also occur (figure 2D) [57-58]. The estimated prevalence of 
CMV retinitis among HIV-infected individuals initiating antiretroviral therapy (ART) in 
sub-Saharan Africa ranges from 0 to 5%, but several studies suggest that this may be 
an underestimation [59-61]. The only available study from South Africa reports a low 
prevalence of CMV retinitis among HIV-infected individuals (1.3%), but reasons for this 
low prevalence remain unclear [62].
2.2 bacterial eye infections
Bacteria can be classified according to their cell wall as Gram-positive or Gram-negative. 
Both Gram-positive (e.g. Staphylococcus aureus and S. albus) and Gram-negative (e.g. 
Pseudomonas aeruginosa and Escherichia coli) bacteria are prevalent causes of eye infec-
tions, in particular infectious conjunctivitis and keratitis (figure 3A-c) [63-64]. Studies on 
the prevalence and spectrum of bacterial eye infections in South Africa are unavailable, 
but one specific bacterium warrants specific attention due to its high prevalence in South 
Africa and the high coinciding prevalence with HIV infection: Mycobacterium tuberculosis.
M. tuberculosis is an aerobic, intracellular, acid-fast bacillus that causes tuberculosis 
(TB). M. tuberculosis is highly prevalent in South Africa. In year 2013, this country had 
the third highest number of TB incident cases globally: 410,000−520,000 cases/year 
[65]. Approximately 62% are co-infected with HIV, which has a destructive effect on 
TB progression and is associated with higher reactivation and recurrence rates [66]. 
Tuberculosis is primarily transmitted through inhalation of M. tuberculosis containing 
aerosols [66]. During primary infection, M. tuberculosis can be eliminated immediately, 
cause immediate onset of active disease (primary disease) and/or will establish a lifelong 
latent infection. The stage of TB infection is in part determined of the host’s immune 
system [66-67]. Reactivation may occur several years later due to deprived immunity as-
sociated with co-morbidities like HIV co-infection [66-67]. Tuberculosis is a major cause 
of morbidity worldwide and predominantly affects the lungs, but can cause disease in 
many human organs including the brain, ileum and eyes [66]. The bacterium may reach 
the eye following haematogenous dissemination from pulmonary or extrapulmonary 
sites, per direct ocular infection or cause ocular disease, especially choroiditis, via an al-
lergic/hypersensitivity reaction incited by M. tuberculosis. Ocular TB diseases, including 
interstitial keratitis and uveitis (figure 3D), cause significant eye morbidity in endemic 
countries, particularly in settings with high HIV prevalence [68-69].
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2.3 laboratory diagnostics in eye infections
Ocular infections, untreated or inappropriately treated, may lead to serious eye com-
plications including visual impairment and blindness. Early diagnosis and subsequent 
initiation of adequate antimicrobial treatment is of paramount importance for good 
visual outcome [70-71]. Although initiation of empirical treatment based on patient’s 
history and clinical characteristics might be feasible in some cases, misdiagnosis may 
occur when different pathogens present with similar clinical characteristics leading to 
devastating visual outcomes. Therefore, antimicrobial treatment must be initiated or 
altered on the basis of both clinical and microbiological evaluation and subsequent 
clinical response to therapy. A wide range of investigative modalities are available that 
supplement clinical diagnosis that provide supportive evidence for disease manage-
ment.
A B
C D
figure 3. Clinical presentation of bacterial eye diseases. (A) Bacterial conjunctivitis accompanied by con-
junctival chemosis with profuse, hyperacute purulent discharge due to infection with Neisseria gonorrhoe-
ae. (b) Bacterial keratoconjunctivitis accompanied by severe conjunctival chemosis and swelling of the 
upper eyelid with mucopurulent discharge and severe corneal ulceration with corneal perforation due to 
Staphylococcus aureus. (c) Corneal ulceration with hypopyon and hyperaemia of the conjunctiva due to 
Pseudomonas aeruginosa. (D) A chorioretinal granuloma, papilledema, retinal vasculitis and mild vitritis due 
to Mycobacterium tuberculosis.
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Conventional microbiological examination of clinical samples obtained from the site 
of ocular infection (e.g. microscopy of stained cornea/conjunctival smears and culture 
for suspected bacteria and viruses) are often performed to determine the causative 
pathogen [72]. Whereas bacterial conjunctivitis cases are usually self-limiting or respond 
well to broad-spectrum antibiotics, certain clinical characteristics and cases require 
further investigation for determination of the alternative pathogen involved as addi-
tional treatment is needed [73]. For example, hyperacute purulent discharge and eyelid 
oedema may indicate involvement of N. gonorrhoeae, a sexually transmitted pathogen 
that requires additional systemic therapy [73]. Swabbing or scraping the site of the 
corneal infiltrate or ulcer should be performed to diagnose infectious keratitis. Thor-
ough microscopic examination of ocular tissue or fluid specimens (e.g. bacterial Gram 
staining or virus antigen-specific immunocytology) may provide rapid identification of 
the pathogen involved, but further culture and subsequent drug sensitivity testing of 
the bacterium or virus may be necessary for adjusted treatment options. Whereas Gram 
staining is used to demonstrate the presence of bacteria, fungi and parasites, potassium 
hydroxide wet mounts are recommended to identify bacterial and fungal elements 
[72]. Microbial culture should be performed in both bacterial and fungal media, which 
should be examined for growth daily and incubated for >2 weeks [72]. If bacteria are 
grown, subsequent drug susceptibility testing is optional to determine the most effec-
tive antibiotic treatment. Microscopic examination and microbial culture of intra-ocular 
samples (e.g. vitreous fluid or retinal biopsy) are rarely used, but might be helpful to 
distinguish between infectious and non-infectious causes of uveitis. Especially in cases 
who are refractory to treatment [74-75].
Although confirmation by microscopic examination and microbial culture remains 
the gold standard to identify the triggering pathogen in most microbial eye infections, 
these assays are time consuming and have a low sensitivity leading to delayed or even 
false negative diagnosis, respectively [72, 76]. Molecular diagnostic utilities, particu-
larly polymerase chain reaction (PCR) analysis are rapid (hours instead of days/weeks), 
specific and more sensitive [72, 76]. PCR analysis are commonly performed on nucleic 
acids isolated from corneal swabs or scrapings of keratitis patients, and in case of uveitis 
aqueous humour or vitreous fluid (figure 4). Specific primer/probe sets have been 
designed to detect the majority of ocular disease inducing viruses with high specificity 
and sensitivity [77-79].
Only few laboratory tests have additional value in the diagnostic process of eye in-
fections [81-82]. Serological analysis may be helpful if ocular syphilis or toxoplasmosis 
is suspected as the clinical picture in these conditions is most often atypical. Clinical 
diagnosis can therefore be confirmed by serological detecting of antibodies against 
Treponema pallidum or Toxoplasma gondii [81, 83]. A supplementary test to PCR is detec-
tion of local antibody production to the triggering pathogen. This includes quantitative 
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total IgG and pathogen-specific IgG testing in the intra-ocular fluid and paired serum. 
Local intra-ocular antibody production, defined as Goldmann-Witmer coefficient (GWC), 
has shown its additional diagnostic value diagnosing patients with infectious uveitis 
[71]. Whereas pathogen-specific nucleic acids commonly become undetectable 2 weeks 
after the onset of disease, specific antibodies remain detectable for many weeks in intra-
ocular fluid. PCR and GWC are therefore complementary and contribute considerably to 
the differential diagnosis of infectious uveitis [71].
3. HIV AnD tHE EyE
3.1 Virology and clinical disease
HIV is a member of the family Retroviridae, subfamily Lentivirinae and genus Lentivirus 
[84]. HIV can be divided into two major types: HIV type 1 (HIV-1) and type 2 (HIV-2). 
HIV-1 is the most pathogenic and most prevalent HIV type worldwide, whereas HIV-2 is 
restricted to western Africa [84]. Hereafter ‘HIV’ refers to HIV-1 unless stated otherwise. 
Sub-Saharan Africa is highly affected by the epidemic of HIV with an estimated 25.8 
million HIV-infected individuals in 2014 (figure 5) [85]. South Africa has the largest HIV 
epidemic worldwide, with an estimated 6.8 million HIV-infected individuals and an HIV 
prevalence of 18.9% in adults aged between 15 to 49 years old [86].
iris
lid speculum
lid speculum
lens
cornea
iris
lens
figure 4. Photograph and schematic overview of anterior chamber paracentesis for the aspiration of aque-
ous humour [80].
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HIV targets several human cells including CD4 T-cells, macrophages and dendritic cells 
[84, 87]. Untreated HIV infection leads to high viremia and subsequent depletion of CD4 
T-cells causing immunodeficiency (figure 6) [87]. In the advanced stage of the disease, 
HIV-infected individuals are at increased risk to develop opportunistic infections and 
tumours. Advanced immunodeficiency will lead to death [87-88].
Currently there is no cure for HIV, but available ART has made HIV infection a treatable 
chronic viral disease [89]. ART consists of a combination of drugs that target the HIV 
life cycle in order to stop HIV replication [88]. In South Africa, the first line treatment of 
HIV in all new patients is the combination of a nucleotide reverse transcriptase inhibi-
tor (Tenofovir), a nucleoside reverse transcriptase inhibitor (Emtricitabine) or cytosine 
analogue (Lamivudine) and a non-nucleoside reverse transcriptase inhibitor (Efavirenz), 
preferably in a fixed dose combination which became available in South Africa in April 
2013 [90]. Initiation of ART results in prolonged disease-free survival, reduced viremia, 
immunologic repletion of CD4 T-cells and reductions in hospitalization and mortality 
[91-94]. Early start of ART before the CD4 T-cell counts drops below 200 cells/ml, results 
in a near-normal quality of life and life expectancy in HIV-infected adults [93-94]. In 
South Africa, the ART eligibility criteria are constantly adapted to new insights. Until 
2015, lifelong ART was initiated in adults if CD4 T-cell counts was ≤350 cells/mm³ or in 
figure 5. Estimated HIV prevalence among adults (15-49 years) in African countries [86]. Note. This figure is 
based on the most recent data from the UNAIDS (Joint United Nations Programme on HIV/AIDS). Intensity 
red colour of countries refers to the HIV prevalence. Countries with the lightest colour have a prevalence 
rate of <0.1% and countries with the darkest colour a prevalence rate of 10.6% to 27.7%. Countries with no 
HIV prevalence data available are in grey.
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adults with severe HIV disease (WHO stage 3 or 4) irrespective of the CD4 T-cell count 
[90]. Although recent insights show benefits of ART initiation directly after confirmed 
diagnosis of HIV infection in all individuals regardless of their CD4 T-cell count, the 
current South African guideline uses a CD4 T-cell threshold of ≤500 cells/mm³ [95-96]. 
Unfortunately, despite recent scale-up of ART services, estimated ART coverage in South 
Africa is still low, especially in rural settings [86]. As a result, many patients are initiated 
at low CD4 T-cell counts putting them at increased risk for disease for HIV related condi-
tions including ocular diseases.
3.2 Eye disease associated with HIV
Eye disease and its complications occur in 50-75% in HIV-infected individuals at some 
point during the course of their illness and are strongly associated with level of immuno-
deficiency; an eye disease might even be the first clinical sign of HIV infection [54, 59]. The 
clinical spectrum of eye disease in HIV-infected individuals is extensive and most ocular 
tissues can be affected (table 4) [97-98]. HIV-associated eye diseases are categorised 
into four groups: (1) eye infections, (2) unusual malignancies, (3) vascular and metabolic 
eye disease and (4) neuro-ophthalmic disease. As the spectrum of eye disease in HIV is 
extensive, only the most common and important presentations will be discussed.
In resource-poor settings, eye infections are the most common and devastating HIV-
associated ocular diseases: mainly infectious keratitis and uveitis [98]. Infectious keratitis 
is usually due to VZV or HSV-1 causing recrudescent keratitis due to viral reactivation al-
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though bacterial and fungal keratitis also occurs. HIV-induced immunosuppression not 
only results in higher recurrence rates of VZV or HSV-1 keratitis, but also causes a more 
severe clinical course leading to significant ocular morbidity [59, 97, 99-100]. In addition, 
HZO warrants special attention as it is a strong marker for HIV infection in individuals 
<40 years of age [54]. Early recognition and testing for HIV can prevent serious ocular 
complications by initiation of oral and topical antiviral treatment as well as initiation 
of ART if required. Infectious uveitis can be caused by a wide variety of pathogens and 
geographic differences are described. In Western countries, CMV retinitis is still the most 
common cause of eye disease before the initiation of ART. In the pre-ART era, up to 
40% of HIV-infected individuals had CMV retinitis, typically when CD4 T-cell counts were 
below 50 cells/mm³ [59, 97]. In sub-Saharan Africa, CMV retinitis is relatively uncommon, 
occurring in <5% of HIV-infected individuals [31, 101]. In contrast to developed countries, 
TB is considered the most important opportunistic infection in HIV-infected individuals 
in sub-Saharan Africa. Ocular morbidity caused by M. tuberculosis is therefore expected 
to be high in sub-Saharan Africa. Disease manifestation in HIV-infected individuals is 
usually atypical compared to non-infected persons, making it difficult to diagnose the 
disease leading to undertreatment [67, 102-104].
Despite their minimal impact on vision, two HIV-associated ocular malignancies war-
rant attention in sub-Saharan Africa: (1) squamous cell carcinoma of the conjunctiva 
table 4. Eye conditions associated with HIV [98-99].
Site of condition condition
External eye (adnexal and orbital) Orbital cellulitis due to Aspergillus spp. infection
Non-Hodgkin’s lymphoma
Herpes zoster ophthalmicus
Molluscum contagiosum of the eyelid
Kaposi’s sarcoma of eyelid and conjunctiva
Keratoconjunctivitis sicca
Squamous cell carcinoma of conjunctiva
Conjuntival microvasculopathy
Anterior segment Infectious keratitis
Anterior uveitis
Posterior segment Endophthalmitis due to Candida spp. infection
Cytomegalovirus retinitis
Syphilis retinitis
Acute retinal necrosis
Progressive outer retinal necrosis
Pneumocystis choroiditis
Tuberculous chorioretinitis
Toxoplasmic chorioretinitis
HIV retinopathy
neuro-ophthalmic Neurosyphilis
Cryptococcal meningitis
Toxoplasmosis of central nervous system
Lymphoma of central nervous system
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(SCCC) and (2) Kaposi’s sarcoma (KS). SCCC is a cancer of the epithelial surface of the 
eye that has become more common in sub-Saharan Africa, particular in young indi-
viduals and more aggressive due to the HIV epidemic [105]. The incidence of SCCC in 
sub-Saharan Africa is currently 3.4 cases per 100,000 men/year [105]. HIV infection is a 
major risk factor for the development of SCCC and is associated with a higher recurrence 
rate after treatment [105-108]. KS, a painless mesenchymal tumour, is also strongly as-
sociated with HIV infection [98, 108-109]. KS aff ects the skin and mucous membranes 
and is caused by HHV-8 infection [98, 109-110]. Ocular KS mainly involves the eyelids 
and conjunctiva [110]. In sub-Saharan Africa, KS is considered the most frequently HIV-
associated malignancy, however geographic diff erences have been reported [111]. A 
study among HIV-infected individuals on ART in South Africa reported the KS incidence 
rate is substantial: 138/100,000 person-years [111].
Vascular and metabolic complications of HIV in the eye are very common aff ecting up 
to 70% HIV-infected individuals, but normally causes only mild visual impairment [59, 
97, 112]. Microvascular changes due to HIV aff ect several tissues of the eye including 
the conjunctiva, optic disc and the retina. HIV retinopathy is the most common vascular 
complication [97, 112]. HIV retinopathy is a retinal microvasculopathy characterised by 
cotton-wool spots (i.e. infarcts of the nerve fi bre layer), intraretinal haemorrhages and 
retinal microaneurysm [112-113]. The pathogenesis of HIV retinopathy remains largely 
unknown, but haemorheologic abnormalities like increased plasma viscosity and circu-
lating HIV-specifi c immune-complexes are involved [112-113]. Analogous to other HIV-
associated eye diseases like CMV retinitis, HIV retinopathy tends to occur more often in 
advanced HIV infection when the CD4 T-cell counts drop below 100 cells/mm³ [97, 101].
The introduction of ART has resulted in a decrease in the incidence of most eye dis-
eases, especially CMV retinitis [114-115]. However, ART also led to an increase of eye 
conditions such as ocular immune reconstitution infl ammatory syndrome (IRIS), a com-
mon and serious short-term complication that may develop 8-16 weeks following ART 
initiation and usually manifests as uveitis referred to as immune recovery uveitis (IRU) 
[116]. The incidence of IRU in South Africa is unknown, but estimates suggest a preva-
lence ranging from 0.11 to 0.83 per person/year with a reported point prevalence up to 
20% among HIV-infected individuals who develop ART-mediated IRIS [117]. Although 
available studies, predominately performed in developed countries, showed a strong 
association with a history of CMV infection, other pathogens such as HSV-1, VZV and 
M. tuberculosis may also play a role in the development of IRU [118-121]. Important risk 
factors for developing IRU include low CD4 T-cell counts at baseline before ART initiation 
and fast onset of retroviral suppression [116]. Alternatively, long-term complications of 
ART led to a rise of metabolic and vascular causes of ocular disease such as cataract and 
hypertensive retinopathy, which are considered serious complication of HIV infection 
and ART therapy [114-115].
25
General introduction
4. EyE cArE In SOutH AfrIcA
Eye care is provided at all healthcare levels in South Africa with primary eye care (PEC) 
as the cornerstone. PEC involves eye care rendered by professional, non-ophthalmic or 
ophthalmic, rural healthcare workers [122]. The idea of PEC was primarily founded to 
reduce the two most important causes of blindness in developing countries: vitamin-A 
defi ciency and trachoma. Currently, PEC is an effi  cient and benefi cial way of reaching ru-
ral communities and plays a crucial role in primary healthcare in South Africa [122-123]. 
PEC is based at primary healthcare (PHC) and community healthcare (CHC) facilities with 
referral to the eye clinic at the local hospital (figure 7). In rural settings, eye units at 
these hospitals are run by optometrists and specialized ophthalmic nurses [124-125]. As 
such, the PHC/CHC facility is the fi rst point of eye care for many patients. However, PEC 
faces a large number of challenges and the quality of eye care in the primary healthcare 
setting varies extensively.
In general, the status of public eye care in South Africa is poor and contrasts the 
private sector in South Africa and that of public eye care in Western countries, but the 
quality varies considerably between urban and rural areas. For example, ophthalmolo-
gists are mainly concentrated in urban areas leaving rural communities far away from 
the highest quality of eye care professionals [123]. Eff ective eye care depends on many 
factors with the availability of budget, essential resources and drugs, human resources 
and referral and mobility options as most important. Data from South Africa are limited 
with regard to eye services at PHC level and referral hospitals, especially in rural settings 
Eye clinic at tertiary hospitals (Provincial, national, and central hospitals)
Optometrists, ophthalmic nurses, general doctors, and ophthalmologists 
Eye clinics at District and regional hospitals
Optometrists and ophthalmic nurses
Professional non-ophthalmic and ophthalmic rural healthcare workers
figure 7. Eye care pyramid in South Africa.
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[124]. Available data from sub-Saharan African countries reported poor eye care quality, 
with limited practitioners-to-patient ratios, inadequate resources, inaccessible services, 
poor state funding and a lack of educational programs as major causes [126]. To improve 
the quality of eye care and to eliminate avoidable blindness, a global initiative was initi-
ated in 1999 by the WHO and the International Agency for the Prevention of Blindness 
(Vision 2020: the right to sight) [127]. This program provided a paradigm shift in the way 
of thinking from individual patient to population care and impressive achievements in 
eye care provision were reported [128]. Vision 2020 was updated in 2013 by the WHO 
Global Action Plan 2014-19 (Towards Universal Eye Health) with the goal to reduce 
avoidable visual impairment as a global public health problem and to secure access to 
rehabilitation services for the visually impaired individuals [129]. The target was set on 
the reduction in prevalence of avoidable blindness and visual impairment by 25% by 
2019 through (1) data collection on prevalence of visual impairment, (2) training of more 
eye care professionals, (3) provision of comprehensive eye care and (4) elimination of 
social and economic obstacles. Although South Africa takes part in the WHO Global Ac-
tion Plan activities, eye care in South Africa still faces many challenges, especially in rural 
settings where the burden of eye disease is highest [Schaftenaar E; unpublished data]. 
Lack of ophthalmological expertise and skills, essential resources, ophthalmic drugs and 
referral systems are major challenges in rural settings that stress the need of urgent 
in-depth health system strengthening [Schaftenaar E; unpublished data].
5. StuDy SEttIng
All studies included in this thesis were conducted in South Africa, with the rural Mopani 
District of the Limpopo Province as the cornerstone (figure 8). Mopani District is one of 
the national priority districts on basis of poor quality of healthcare and high rates of pov-
erty, illiteracy and unemployment and it has one the highest HIV prevalence rates (24.6% 
among pregnant women in 2013) in South Africa [130]. To provide public healthcare 
services, 100 nurse-managed PHC facilities are available throughout the district. These 
facilities refer to six district hospitals and one regional hospital. Currently, rapid scale-
up of health services including services for eye care is ongoing. However, eye care will 
remain limited to specialist nurses working in few PHC facilities and in most hospitals. 
The only available ophthalmologists in public care are outside the Mopani District at the 
tertiary referral hospital of Mankweng (Capricorn District, Limpopo Province). However, 
due to logistic and operational challenges and high workload, referral to specialist care 
is extremely challenging and frequently problematic.
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6. AIm AnD OutlInE Of tHIS tHESIS
The burden of eye disease in South Africa is considered high, but limited data are avail-
able. The aim of the studies presented in this thesis was to provide novel insight into 
the clinical field of ophthalmology in a high HIV prevalence setting in rural South Africa 
to improve clinical care and visual outcome of patients affected by HIV-associated eye 
diseases. To determine the burden of eye diseases and its relation with HIV infection, 
this thesis focusses on the most important HIV-associated eye infections (keratitis and 
uveitis) and the effects of chronic HIV infection and ART use.
To obtain insight in the potential burden of HHV-related eye diseases, we determined 
the seroprevalence of HHVs in HIV-infected ART-naïve individuals in the rural Mopani 
district in chapter 2 and identified risk factors associated with the HHV seropositive 
status. chapter 3 and chapter 5 describe two cross-sectional studies on the micro-
biological aetiology and clinical manifestations of infectious keratitis and uveitis. Both 
ocular disease entities are well known to cause significant visual morbidity, but data 
from rural settings with high HIV prevalence have been unavailable. The aim of both 
studies was to determine the prevalence and clinical manifestations of different patho-
gens involved and to identify clinical data to improve future diagnosis and management 
of these conditions. chapter 4 expands on both studies and reports on the spectrum of 
ocular complications of VZV infection as we observed a high number of HZO cases with 
figure 8. Map of Africa with South Africa (dark blue), Limpopo Province (light red) and Mopani District 
(dark red) highlighted.
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late ocular complications during the course of these cross-sectional studies. This HZO 
study provides clinical data and recommendations for healthcare workers to improve 
management and outcome of disease. Moreover, it highlights the important role of HIV 
co-infection to prevent future ocular complications and ensure adequate testing and 
counselling for HIV in HZO cases. chapter 6 describes a case of tuberculous chorioreti-
nitis in a HIV-infected adult after recent initiation of ART in rural South Africa that was 
most likely IRIS-associated. Ocular IRIS is a well-known phenomenon after ART initiation, 
but is frequently missed in rural settings. This case report stresses the importance of 
early detection and treatment of ocular immune reconstitution inflammatory syndrome 
and the role of M. Tuberculosis in eye infections. The study described in chapter 7 
determined the occurrence and severity of ocular diseases in HIV-infected individuals 
on ART and indicates that regular ophthalmological monitoring of these individuals is 
warranted to prevent a future large burden of visual impairment.
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AbStrAct
Seroprevalence data of human herpesviruses (HHVs) are limited for sub-Saharan Africa. 
These are important to provide an indication of potential burden of HHV-related dis-
ease, in particular in human immunodeficiency virus (HIV)-infected individuals who are 
known to be at increased risk of these conditions in the Western world. In this cross-
sectional study among 405 HIV-infected and antiretroviral therapy naïve individuals in 
rural South Africa the seroprevalence of HHVs was: herpes simplex virus type 1 (HSV-1) 
(98%), herpes simplex virus type 2 (HSV-2) (87%), varicella zoster virus (VZV) (89%), and 
100% for both Epstein-Barr virus (EBV) and cytomegalovirus (CMV). Independent factors 
associated with VZV seropositivity were low educational status and having children. 
Lack of in-house access to drinking water was independently associated with positive 
HSV-1 serostatus, whereas Shangaan ethnicity was associated with HSV-2 seropositivity. 
Increasing age was associated with higher IgG titres to both EBV and CMV, whereas CD4 
cell count was negatively associated with EBV and CMV IgG titres. Moreover, IgG titres 
of HSV-1 and 2, VZV and CMV, and CMV and EBV were positively correlated. The high 
HHV seroprevalence emphasizes the importance of awareness of these viral infections 
in HIV-infected individuals in South Africa.
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IntrODuctIOn
Herpes simplex virus type 1 (HSV-1) and 2 (HSV-2), varicella zoster virus (VZV), Epstein-
Barr virus (EBV), and cytomegalovirus (CMV) are human herpesviruses (HHV) that are 
prevalent worldwide. HHV Infections can lead to a variety of clinical conditions that 
range in severity from cold sores and genital ulcers (HSV), and chickenpox (VZV) to po-
tentially sight-threatening (e.g. CMV uveitis and HSV keratitis) or even life-threatening 
diseases such as HSV encephalitis and EBV-associated malignancies [1-3]. Primary HHV 
infections, commonly acquired at young age, lead to a life-long latent infection with in-
termittent reactivation resulting in periodic asymptomatic or recrudescent disease. The 
host immune system is pivotal to resolve lytic infections and to inhibit HHV reactivation 
from latency. Consequently, reactivation of HHV is much more frequent among immu-
nocompromised individuals including those infected with human immunodeficiency 
virus (HIV) [4-5]. Also, HIV-infected individuals have an increased risk of developing more 
severe HHV-related disease [4-5]. Even after the introduction of antiretroviral therapy 
(ART), HIV-infected individuals remain at risk of developing severe HHV-related diseases 
as ART-induced recuperation of adaptive immunity may result in vigorous anti-HHV 
cellular immune responses. In the case of residual ocular CMV infection, restored CMV 
immunity may lead to sight-threatening immune recovery uveitis [6]. HHV infections 
clinically interact with HIV, contribute substantially to hospitalization, morbidity and 
mortality and some HHVs (e.g. HSV-2) may even facilitate HIV transmission [4, 7-8]. This 
is of particular importance in sub-Saharan Africa where HIV prevalence rates are at their 
highest. Despite the roll-out of ART programmes in this region, ART coverage is still 
low [9]. Many HIV-infected patients seek healthcare with considerably more advanced 
immunodeficiency and may present with clinically different HHV-related diseases 
compared to individuals in resource-rich countries. In contrast to developed countries, 
where HHV seroprevalence and occurrence of associated diseases are well-documented, 
there is only scarce information available on the seroprevalence and risk factors of HHV 
infections in sub-Saharan Africa. This information is important to provide an indication 
of the burden of HHV infections which is particularly relevant for HIV-infected individu-
als who are known to be at increased risk for development of HHV-induced disease due 
to reactivation.
mAtErIAl AnD mEtHODS
Study setting and population
Study participants were recruited between September 2012 and January 2013 at primary 
healthcare (PHC) facilities across the Mopani District (Limpopo Province, South Africa), 
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where the two main ethnic groups are Sotho (46%) and Shangaan (44%) [10]. Participat-
ing PHC facilities were selected by ratio of population-size of each of five sub-districts 
with a minimum of two PHC facilities/sub-district. Within each sub-district, PHC facilities 
were selected based on the number of patients on the ‘wellness, pre-ART programme’, 
geographic location and size of the catchment area. Individuals who had an indication 
to draw blood for determination of CD4 count (CD4 T-cells/mm³ blood) were eligible 
for this study. Criteria to participate were adult age (i.e. 18 years and older) and no prior 
ART exposure. Low educational status and low financial income were defined as hav-
ing no education or primary school only, and persons with a government grant as the 
main source of income, respectively. The study was performed according to the tenets 
of the Helsinki Declaration, approved unconditionally by the Human Research Ethics 
Committee (Medical) of the University of the Witwatersrand, Johannesburg, South Africa 
(reference number: M120546), and written informed consent was obtained from all 
participants.
Study and laboratory procedures
Demographic and clinical data were collected upon inclusion. A whole blood sample 
was drawn and diagnostic CD4 counts were determined using the Cytomics FC 500 MPL 
platform (Beckman Coulter). Serological analysis was performed at the Laboratory of 
Viroscience at the Erasmus Medical Center in Rotterdam, The Netherlands. HHV-specific 
serum IgG titres were determined using Serion ELISA classic tests (Virion Serion) on 
the Anthos-Labtec AR8001 platform (Anthos Labtec). ELISAs were performed and data 
interpreted (i.e. seropositive, borderline or seronegative) per manufacturer’s guidelines 
(Virion Serion).
Statistical analysis
Clinical and laboratory data were double-entered and validated using EPI-INFO version 
3.5.4 (Centers for Disease Control). Description of study population and seroprevalence 
is done using number with proportion and mean with standard deviation. To identify 
factors associated with HHV-specific positive serostatus, excluding persons with border-
line ELISA results, univariate analysis was performed using Chi-squared test, or Fisher’s 
Exact test if appropriate, for categorical variables and Mann-Whitney and Student T-test 
for continuous variables. Data are presented as odds ratio (OR) with 95% confidence 
interval (CI), mean with standard deviation (SD) or as median. To identify factors inde-
pendently associated with seropositive status variables with P-values <0.10 in univariate 
analysis, and age and gender as potential confounders, were included in multivariate 
analysis using logistic regression (forward Likelihood Ratio) with HHV seropositivity 
as dichotomous measure of outcome. The potential correlation of log2 HHV IgG titres 
with age and CD4 count was analysed using Spearman’s correlation coefficient. Multiple 
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linear regression analysis was performed to determine potential association of age and 
CD4 count, adjusting for gender and ethnicity, with the log2 HHV titre as continuous 
measure of outcome, providing assumptions for linear regression were met. Statistical 
analyses were conducted using PASW Statistics and P-values <0.05 were considered 
statistically significant.
rESultS
Study population
The study population of 405 HIV-infected and ART-naïve adults consisted of 72 (18%) 
men and 333 (82%) women (table 1). The mean age was 37.9 ± 11.5 years. Men were 
table 1. Demographic characteristics of study participants (n=405).
characteristic
Gender (male) 72 (18)
Age in years (mean (SD)) 38 (11)
Ethnicity
Shangaan 255 (65)
Sotho 138 (35)
Marital status
Never married 243 (60)
Married 129 (32)
Divorced or widowed 33 (8)
Has children 352 (87)
Individuals in household 5.1 (2.3)
Low educational status 192 (47)
Currently employed 103 (25)
Low financial income 184 (46)
In-house access to drinking water 25 (6.2)
In-house access to latrine 20 (5.0)
Keeps livestock 24 (5.9)
CD4 cell count in cells/mm³ (mean (SD)) 382 (226)
Clinical HIV-stagea
Stage 1 344 (85)
Stage 2 25 (6.0)
Stage 3 35 (9.0)
Stage 4 0 (0)
Data are presented as number (%) unless otherwise indicated. SD = standard deviation; HIV = human im-
munodeficiency virus.
aClinical HIV-staging was done according to the WHO Clinical Staging of HIV/AIDS [11].
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significantly older (mean age of 42 versus 37 years, P=0.002), more often employed (age-
adjusted OR (aOR)=4.5; 95% CI: 2.6–7.7, P<0.001), were or had been married (aOR=1.8; 
95% CI: 1.0–3.1, P<0.05) and had lower mean CD4 counts than women (306 vs. 398 cells/
mm³; P<0.001). Most participants had children (87%) and some had limited access to 
in-house drinking water (6.2%) and latrine (5.0%). Thirty (8%) participants were newly 
diagnosed for HIV infection, 354 (87%) attended the ‘wellness, pre-ART programme’ and 
21 (5%) individuals attended the clinic for baseline results before ART initiation. Mean 
CD4 count was 382 ± 226 CD4 T-cells/mm³ and fifty percent of participants had CD4 
counts ≤350 cells/mm³, which is the threshold in South Africa to initiate ART [12].
Seroprevalence of HHVs
HHV seroprevalence was determined in 402 samples (three were unavailable after trans-
port); serum HHV ELISA data are summarized in table 2. Excluding borderline results, 
HHV seroprevalence was very high: HSV-1 98% (95% CI: 96–99%); HSV-2 87% (95% CI: 
83–90%); VZV 89% (95% CI: 86–92%) and 100% for both EBV and CMV. Seroprevalence 
was similar between individuals with CD4 count below and above 350 cells/mm³ for 
HSV-1 (98% vs. 97%; P=0.33), HSV-2 (89% vs. 84%; P=0.17) and VZV (91% vs. 88%; P=0.35). 
Neither HHV seropositive status with CD4 count nor clinical HIV and HHV-related clinical 
symptoms was associated at time of sampling. The frequency of reported HHV-related 
clinical symptoms was low and not associated with the respective HHV seropositive sta-
tus. History of chickenpox was reported by 72 (20%) of VZV seropositive and 5 (12%) of 
VZV seronegative individuals (P=0.2) and herpes zoster by 50 (14%) and 4 (10%), respec-
tively. Among HSV-1 seropositive individuals a history of cold sores and oral lesions was 
reported by 54 (15%) and 49 (14%) study participants, respectively. HSV-1 seronegative 
individuals did not report these diseases. Anogenital lesions were reported by 77 (24%) 
and 10 (20%) HSV-2 seropositive and seronegative study participants, respectively.
table 2. Seroprevalence of human herpesviruses in HIV-infected individuals (n=402).
HSV-1 HSV-2 VZV EbV cmV
Positive 361 (90) 316 (79) 353 (88) 400 (99.5) 402 (100)
borderline 32 (8.0) 37 (9) 7 (1.7) 2 (0.5) 0 (0)
negative 9 (2.2) 49 (12) 42 (10) 0 (0) 0 (0)
Data are presented as number (%). HSV = human simplex virus; VZV = varicella zoster virus; EBV = Epstein-
Barr virus; CMV = cytomegalovirus.
factors associated with positive HHV serostatus
Crude clinical and demographic factors associated with individuals’ HHV seropositive 
vs. seronegative status for HSV-1, HSV-2 and VZV are summarized in table 3. The 100% 
seroprevalence for EBV and CMV precluded calculation of such factors. Adjusting for age 
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figure 1. Scatter plots of factors associated with human herpesvirus-specific serum IgG titres. Correlation 
between serum EBV and CMV IgG titres and the individual’s (A) Age and (b) CD4 cell count. (c) Correlation 
between serum IgG titres of different human herpesviruses. Serum IgG titres, presented as binary logarith-
mic PEI/ml values, were calculated based on corresponding reference sera from the Paul-Ehrlich Institute (Er-
langen, Germany). The Spearman correlation test was used for statistical analysis. HSV-1, herpes simplex virus 
1; HSV-2, herpes simplex virus; VZV, varicella zoster virus; EBV, Epstein-Barr virus and CMV, cytomegalovirus.
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and gender, lack of in-house access to drinking water (aOR=7.7; 95% CI: 1.8–33, P=0.006) 
and Shangaan ethnicity (aOR=2.4; 95% CI: 1.2–4.5, P=0.008) were independently asso-
ciated with positive HSV-1 and HSV-2 serostatus, respectively. Low educational status 
(aOR=4.0; 95% CI: 1.8–9.0, P=0.01), having children (aOR=2.2; 95% CI: 1.0–4.9, P=0.04) 
and a higher number of children in the household (P=0.007) were independently associ-
ated with VZV seropositivity, including adjustment for age and gender (data not shown).
Next, we assayed potential correlations between HHV-specific IgG titres and paired 
individual’s laboratory and clinical data (figure 1). EBV and CMV IgG titres correlated 
significantly with age and CD4 count. Increasing age was associated with higher EBV 
(R²=0.05, P<0.001) and CMV IgG titres (R²=0.03, P=0.0008) (figure 1A), whereas increas-
ing CD4 count was negatively associated with EBV (R²=−0.04, P=0.0001) and CMV IgG 
titres (R²=0.08, P<0.0001) (figure 1b). There was no association of CD4 count with HSV-1, 
HSV-2 and VZV IgG titre (see supplemental figure S1). Higher HSV-1 IgG titres were de-
tected among men (median 88 U/mL versus 66 U/mL in women; P=0.001). Furthermore, 
HSV-1 and HSV-2 (R²=0.03, P=0.007), CMV and VZV (R²=0.02, P=0.013) and CMV and EBV 
(R²=0.18, P<0.0001) IgG titres were positively correlated (figure 1c). No associations of 
age, gender and ethnicity were observed between IgG titres for the other HHVs.
Finally, multivariate analysis of determinants of HHV titre was performed for age, 
gender, ethnicity and CD4 count. In individuals with similar gender and ethnicity, there 
was an association for every one year increase in age (0.17 unit) and every cell reduction 
in CD4 count (−0.25 unit) with CMV IgG titre. Also, for every one year increase in age the 
EBV IgG titre was associated with a 0.17 unit increase in titre in subjects comparable in 
gender, ethnicity and CD4 count, whereas male gender was associated with a decrease 
in HSV-1 IgG tire (−0.17 unit; see supplemental table S1).No associations between HSV-
2 and VZV IgG titres and the aforementioned factors were observed.
DIScuSSIOn
This study reports on the seroprevalence of HSV-1, HSV-2, VZV, EBV and CMV among HIV-
infected and ART-naïve adults in rural South Africa. We showed that HHV seroprevalence 
in this population is very high. We identified several demographic factors that were 
associated with a seropositive status for HSV-1, HSV-2 and VZV, but did not observe that 
clinical history of HHV infection is predictive for the individual’s HHV serostatus.
We observed a relatively high seroprevalence of HHVs which confirms observations in 
other studies addressing seroprevalence of these viruses among HIV-infected individu-
als in Africa. Estimates of HSV-1 and HSV-2 seroprevalence among adult HIV-infected in-
dividuals vary across Africa, ranging from 65 to 90% in studies from South Africa, Kenya, 
Lesotho and Tanzania [13-17]. High prevalence rates (>85%) have also been reported 
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for VZV, CMV and EBV in HIV-infected adult individuals from several African countries 
[13-14, 18]. These infections may be acquired in early childhood as illustrated by the 
100% CMV seroprevalence among a small cohort of city-dwelling HIV-infected children 
in Kenya [19]. As such, a generally high seroprevalence of HHVs is manifest among adults 
with HIV-infection across Africa. It should be noted that we recruited a selected group 
of individuals in our study (HIV-infected and ART-naïve adults) and that our findings 
should not be extrapolated to the general adult African population including either HIV 
negative or HIV positive adults on ART therapy. Since HIV-infection is associated with 
increased HHV seroprevalence, it may be expected that seroprevalence of these viruses 
in the general population would be lower as for example shown for HSV and EBV [1, 20].
We identified several factors associated with seropositive status for 5 individual HHVs, 
but these should be interpreted with caution as seroprevalence was very high, result-
ing in a relatively small group of seronegative participants, and the effect of chance 
associated with multiple comparison cannot be ruled out. In addition, we like to point 
out that the use of prevalence odds ratio instead of prevalence ratio may have resulted 
in an overestimation of the observed associations; although there are pros and cons to 
both measures of effect [21-22]. Low socioeconomic status – represented here as lack 
of in-house access to drinking water – was appeared to be associated with HSV-1 sero-
positivity. Shangaan ethnicity was independently associated with HSV-2 seropositivity, 
suggesting a higher HSV-2 infection rate among Shangaan compared to Sotho. This po-
tential association may be due to different sexual risk behaviour between these ethnic 
groups [unpublished data]. However, our study did not confirm previously described as-
sociations of seropositivity for HSV-2 and female gender, age, and other socioeconomic 
factors, but this may be due to the high seroprevalence in our study population [23-27]. 
As reported earlier, VZV seropositive status associated independently with age, low 
educational status, having children and number of children, and number of individuals 
in the household [28-32]. Notably, no association was observed between the individual’s 
seropositive HHV status and a history of corresponding HHV-specific clinical symptoms. 
This could be due to recall bias as some infections would have occurred in early child-
hood (e.g. varicella); other infections can have a subclinical course (e.g. CMV, HSV) with-
out ever presenting with clear symptoms or being recognised by the individual. As such, 
based on the poor predictive value, it would not be possible to identify individuals with 
seropositive status, and thus at increased risk of HHV reactivation and complications, 
based on clinical history taking.
We observed a moderate positive associations between EBV and CMV IgG titres and 
age. As most individuals are infected with HHV during childhood, increasing reactivation 
rates of the respective HHVs during ageing and/or progress of HIV infection may have 
attributed to this association [33-34]. Indeed, age-related waning of cellular immunity 
and higher reactivation rates of latent HHVs resulting in increased HHV-specific IgG and 
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IgM titres have been reported [33, 35-36]. The negative association of EBV and CMV IgG 
titres with CD4 count is in line with two recent studies describing significant increase 
of activated HHV-specific CD4 T-cells in HIV-infected individuals compared to HIV naïve 
individuals [37-38]. Decreasing CD4 count due to HIV replication is associated with acti-
vation of CMV- and EBV-specific CD4 T-cells as part of chronic immune activation, which 
may subsequently stimulate humoral responses and produce higher IgG titres in time.
The observed weak, though significant associations between serum IgG levels of dif-
ferent HHVs suggest that risk factors of reactivation leading to higher IgG titres partially 
overlap. The associations between HSV-1 and HSV-2, and EBV and CMV IgG titres may 
in part be attributed to the anatomic and cellular site and corresponding immune re-
sponses involved in controlling viral latency. Both HSV types establish latency in sensory 
neurons, whereas lymphocytes are the main cell type of CMV (hematopoietic progenitor 
cells) and EBV (B-cells) latency [39-41]. HIV infection may inhibit specific immune cell 
types and mechanisms that are commonly involved in controlling either latent neuro-
tropic (HSV-1 and HSV-2) and lymphotropic (EBV and CMV) herpesviruses. Moreover, the 
positive association between age and CD4 count with both EBV and CMV strengthen 
this assumption that immunity to both viruses is entangled, which warrants further 
studies [36]. However, contrary to our results, the observed association in the latter 
study was between CMV and HSV-1 IgG titres and was only significant in individuals <45 
years old. In addition, CMV seropositivity, but not CMV IgG titres, has been associated 
with increased VZV IgG titres [34]. Since all individuals in our study cohort were CMV 
seropositive a similar association analysis could not be performed.
There are several limitations to this study. First, PHC facilities were not randomly se-
lected within the five sub-districts in Mopani, which may have resulted in some degree 
of bias in obtaining a population estimate for the Mopani District. However, since PHC 
facilities were sampled by ratio of sub-district’s population-size with a minimum of two 
PHC facilities per sub-district and no geographical variation was observed, we consider 
our study cohort representative for HIV-infected individuals attending PHC facilities in 
the Mopani district. Second, only individuals attending PHC facilities were included, a 
population that may be different for some demographic characteristics compared to 
those not seeking healthcare. Generally, the latter group ultimately presents with lower 
CD4 counts and higher risk of HHV-related disease suggesting an under- rather than 
overestimate of seroprevalence. Third, considerably more women than men were in-
cluded in this study, but statistical analyses were adjusted for gender. Fourth, the use of 
self-reported clinical history of HHV infection may have resulted in some degree of recall 
bias, especially since all participants were adults. Finally, we did not include HHVs type 
6 and 8 in our seroprevalence study; HHV-8 in particular is associated with morbidity 
(Kaposi sarcoma) in HIV-infected individuals.
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HHV infections have currently limited priority and awareness in the (pre-)ART pro-
gramme of South Africa. The herein reported high HHV seroprevalence and consequent-
ly high risk for HHV-related diseases among HIV-infected individuals warrant increased 
awareness among healthcare workers in rural South Africa for early clinical signs of 
these conditions to initiate prompt antiviral treatment: e.g. early diagnosis and treat-
ment of herpes zoster ophthalmicus to prevent corneal blindness [4, 6]. In conclusion, 
seroprevalence of HHVs in rural South Africa is very high and recognition and awareness 
of HHV-related diseases is warranted.
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SuPPOrtIng InfOrmAtIOn
figure S1. Scatter plots of age and CD4 cell count with specific serum IgG titres for HSV-1, HSV-2 and VZV. 
Serum IgG titres, presented as binary logarithmic PEI/ml values, were calculated based on corresponding 
reference sera from the Paul-Ehrlich Institute (Erlangen, Germany). The Spearman correlation test was used 
for statistical analysis. HSV-1, herpes simplex virus 1; HSV-2, herpes simplex virus; VZV, varicella zoster virus.
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table S1. Results of multivariate linear regression analysis of age, gender, ethnicity and CD4 cell count with 
log2 IgG titre of individual human herpes viruses.
beta P-value r² f-statistic P-value
HSV-1 Igg titre
Intercept 6.96
Age −0.02 0.8 0.035 3.13 0.02
Gender −0.17 0.002
Ethnicity −0.01 0.9
CD4 cell count −0.04 0.5
HSV-2 Igg titre
Intercept 6.09
Age 0.09 0.1 0.014 1.11 0.4
Gender 0.04 0.5
Ethnicity −0.06 0.3
CD4 cell count 0.06 0.3
VZV-1 Igg titre
Intercept 10.6
Age −0.05 0.4 0.006 0.54 0.7
Gender −0.05 0.3
Ethnicity −0.02 0.38
CD4 cell count −0.03 0.6
EbV Igg titre
Intercept 7.31
Age 0.17 <0.001 0.027 3.66 0.006
Gender −0.03 0.5
Ethnicity −0.04 0.5
CD4 cell count −0.07 0.2
cmV Igg titre
Intercept 9.34
Age 0.17 0.001 0.076 8.92 <0.001
Gender 0.04 0.4
Ethnicity 0.03 0.6
CD4 cell count −0.25 <0.001
HSV, herpes simplex virus; VZV, varicella-zoster virus; CMV, cytomegalovirus; EBV, Epstein-Barr virus.
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AbStrAct
The purpose of this investigation was to determine the clinical and corneal microbial 
profile of infectious keratitis in a high human immunodeficiency virus (HIV) prevalence 
setting in rural South Africa. Data in this cross-sectional study were collected from 
patients presenting with symptoms of infectious keratitis (n=46) at the ophthalmology 
outpatient department of three hospitals in rural South Africa. Corneal swabs were 
tested for herpes simplex virus type 1 (HSV-1) and 2 (HSV-2), varicella zoster virus (VZV) 
and adenovirus DNA by real-time polymerase chain reaction (PCR) and for bacteria and 
fungi by culture. Based on clinical history, disease characteristics and laboratory results, 
29 (63%) patients were diagnosed as viral keratitis, including 14 (48%) viral keratitis cases 
complicated by bacterial superinfection, and 17 (37%) as bacterial keratitis. VZV and 
HSV-1 DNA was detected in 11 (24%) and 5 (11%) corneal swabs, respectively. Among 
clinically defined viral keratitis cases, a negative viral swab was predominantly (93%) 
observed in cases with subepithelial inflammation and was significantly associated with 
an increased duration of symptoms (P=0.003). The majority of bacteria cultured were 
Gram-positive (24/35), including Staphylococcus epidermidis and S. aureus. Viral aetiol-
ogy was significantly associated with a history of herpes zoster ophthalmicus (P<0.001) 
and a trend was observed between viral aetiology and HIV infection (P=0.06). Twenty-
one (47%) keratitis cases were complicated by anterior uveitis, of which 18 (86%) were 
HIV-infected cases with viral keratitis. The data implicate a high prevalence of herpetic 
keratitis, in part complicated by bacterial superinfection and/or uveitis, in HIV-infected 
individuals presenting with infectious keratitis in rural South Africa.
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IntrODuctIOn
Infectious keratitis is a major cause of ocular morbidity worldwide and the most common 
cause of unilateral corneal blindness in low-resource settings [1]. The estimated popula-
tion incidence of infectious keratitis in these settings is up to 800 per 100,000/year, which 
is about 70-times higher than in high-resource settings [1]. Early diagnosis is essential as 
visual outcome depends on prompt initiation of targeted antimicrobial treatment [2-3]. 
The spectrum of keratitis-associated pathogens is diverse and includes viruses, bacteria, 
fungi and protozoa. Moreover, the clinical picture and aetiology of infectious keratitis 
varies geographically as it is subject to both environmental and host factors [1-2].
Viruses, in particular human alpha herpesviruses, are well-known in Western coun-
tries for causing recurrent and devastating keratitis, but data from sub-Saharan African 
countries are scarce and solely based on clinical diagnosis [4-6]. The high human im-
munodeficiency virus (HIV) prevalence in this region may play an important role in the 
distribution of keratitis-associated pathogens as HIV-infected individuals are at higher 
risk for viral keratitis, particularly varicella zoster virus (VZV) keratitis [7]. However, man-
agement of infectious keratitis in this region predominantly involves (presumptive) 
antibiotic and/or anti-fungal treatment, which may lead to inappropriate treatment of 
patients with viral keratitis thereby increasing the risk of visual disability [8]. Elucidation 
of both the aetiology of infectious keratitis, in particular the potential role of viruses, and 
the associated clinical picture in a high HIV prevalence setting such as rural South Africa 
is of paramount importance to improve diagnosis and clinical management aimed to 
prevent visual impairment and blindness.
The aim of the current study was to determine the clinical and corneal microbial pro-
file of infectious keratitis in a high HIV prevalence setting in rural South Africa.
mAtErIAl AnD mEtHODS
Study population and setting
This cross-sectional study was conducted at the ophthalmology outpatient department 
of three hospitals in rural South Africa (Mopani District) between September 2013 and 
May 2015. Criteria for participation were adult age (≥18 years old), no recent history of 
ocular surgery or trauma, willingness to test for HIV and a clinical diagnosis of keratitis 
based on slit-lamp examination: inflammation of the cornea with or without the pres-
ence of a corneal epithelial defect [2-3, 9]. Contact lens wearers were excluded. Infec-
tious keratitis was classified as viral, bacterial, fungal and/or protozoan on the basis of 
clinical history (e.g. history of unilateral painful skin rash in the dermatomal distribution 
of the trigeminal nerve as a sign of VZV infection), disease characteristics (e.g. typical 
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herpetic corneal dendrites, disciform keratitis or an epithelial defect associated with a 
larger infiltrate as a sign of bacterial keratitis), laboratory results and response to initi-
ated treatment according to current diagnostic criteria [3, 10-11]. Infectious keratitis 
patients presenting with uveitis were defined as keratouveitis. Treatment of infectious 
keratitis was initiated according to standard treatment guidelines for hospitals from the 
Department of Health of South Africa [12]. Ethical clearance for this study was obtained 
from the Human Research Ethics Committee (University of the Witwatersrand; Johan-
nesburg, South Africa; project ID: M130201). Written informed consent was obtained 
from all participants.
Ophthalmic examination
Demographic and clinical data were collected using a questionnaire and full ophthalmic 
examination performed, including visual acuity using an “illiterate E” Snellen chart at a 
distance of 6 meters, slit lamp examination, intraocular pressure using the Icare TA01i 
(Icare Finland Oy; Helsinki, Finland) and dilated indirect funduscopy. Visual acuity after 
treatment was also determined at routine clinical follow-up visits. Visual impairment was 
defined according to the International Classification of Diseases on the basis of the in-
dividual’s visual acuity [13]. Counselling and HIV testing following routine practice were 
performed for all participants who reported to be HIV-uninfected or were unaware of 
their HIV status. Diagnostic CD4 counts were determined in all HIV-infected participants.
laboratory analyses
Corneal samples were collected from the affected eye under topical anaesthesia using a 
corneal swab and an eyelid spreader to prevent contamination from the eyelids. Due to 
the lack of ophthalmological care in this region, we chose to perform corneal swabbing 
instead of corneal scraping as complications due to corneal swabbing are less likely to 
occur. All samples were collected by the same investigator (author ES). First, a corneal 
swab for virus detection was obtained in 5 mL collection medium (Puritan diagnostics; 
Guilford, CT). Viral swabs were examined for herpes simplex virus type 1 (HSV-1), HSV 
type 2 (HSV-2), VZV and adenovirus DNA by real-time PCR using virus specific primer/
probe combinations at the diagnostic laboratory of the department Viroscience (Eras-
mus Medical Center; Rotterdam, The Netherlands) as described elsewhere [14]. The 
sensitivity of the virus-specific real-time PCR assays, as defined by the 95% hit rate on 
the electron microscopy counted virus stocks, was about 100 virus genome-equivalent 
copies/mL. A second swab (TransystemTM) for bacterial and fungal culture (Copan 
diagnostic Inc.; Murrieta, CA) was obtained from the same eye. Microbial examination, 
including Gram-stain microscopy and culture was performed on swabs for bacteria and 
fungi at the Lancet Laboratory according to standard diagnostic procedures (Tzaneen, 
South Africa).
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Statistical analysis
Data were double-entered into EPI-INFO version 3.5.4 (Centers for Disease Control; 
Atlanta, GA) and analysed using IBM SPSS Statistics version 22 (IBM; New York City, NY). 
Descriptions of study population and clinical and laboratory findings is performed using 
number with proportion and median with interquartile range (IQR) and stratified to HIV 
status. Demographic, clinical and laboratory factors were compared between different 
aetiologies of keratitis to identify factors associated with infectious keratitis. Comparison 
was done by Chi-squared tests with Fisher’s Exact if appropriate for categorical variables 
and Mann-Whitney for continuous variables. Data are presented as odds ratio (OR) with 
95% confidence interval (CI) or as median with IQR.
rESultS
Demographics and clinical presentation
We recruited 46 patients clinically diagnosed with infectious keratitis, consisting of 29 
(63%) women and 17 (37%) men with median age of 41 (IQR 31–59) years (table 1). 
Twenty-eight (61%) participants were HIV-infected of which 6 (21%) were tested reac-
tive to HIV for the first time and 13 (46%) were on antiretroviral therapy (ART). Median 
CD4 count at enrolment was 226 (IQR 156–329) CD4 T-cells/mm³ for those on ART and 
299 (IQR 160–396) CD4 T-cells/mm³ for ART naïve participants.
Reduced vision was the most common complaint reported at enrolment (100%) fol-
lowed by eye pain (96%), tearing (72%) and photophobia (65%). Median duration of 
symptoms was 19 (IQR 11–38) days. Twenty-six (57%) patients had been referred from a 
primary healthcare (PHC) facility. Fourteen (30%) patients reported use of topical anti-
biotic eye ointment (Chloramphenicol) prior to inclusion, unfortunately only 3 patients 
(21%) used the ointment adequately. At ophthalmic examination, an epithelial defect 
was the most common observed clinical characteristic (65%) followed by signs of an-
terior chamber inflammation (52%). Corneal infiltration was the most common clinical 
characteristic associated with an epithelial defect (33%) followed by corneal dendrites 
(27%), punctate epithelial keratitis (20%) and corneal ulceration (20%). In cases of sub-
epithelial inflammation, stromal keratitis was the most observed clinical characteristic 
(56%) followed by subepithelial infiltration (31%) and endothelial inflammation (13%). 
An intraocular pressure of >21 mmHg was observed in 9 of 43 (21%) patients.
microbial laboratory analyses on corneal swabs
Viral DNA was detected from corneal swabs in 16 of 45 (36%) patients; one viral corneal 
swab was unavailable for viral diagnostics. Whereas HSV-2 and adenovirus DNA was un-
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detectable by PCR, 11 (24%) and 5 (11%) swabs were positive for VZV [median PCR cycle 
threshold (Ct) value of 37.0 (IQR 32.2–38.9)] and HSV-1 [median PCR Ct value of 33.0 (IQR 
26.6–36.7)] DNA, respectively (table 2). Bacteria were cultured from corneal swabs of 29 
(63%) patients, mainly Gram-positive bacteria (69%) with Staphylococcus epidermidis as 
the most common detected bacterium (36%) followed by S. aureus (14%) and S. capitis 
(9%). Based on clinical history, disease characteristics, laboratory results and response to 
initiated treatment (i.e. antibiotics or antiviral), 29 (63%) patients were diagnosed as viral 
keratitis, including 14 (48%) viral keratitis cases complicated by bacterial superinfection 
and 17 (37%) as bacterial keratitis (table 2).
Among patients diagnosed with viral keratitis, 15 (52%) corneal swabs were positive for 
viral DNA and 14 (48%) were negative. Positive viral swabs were predominantly obtained 
from cases with epithelial inflammation (67%) with dendritic corneal lesions (70%) as the 
most common epithelial inflammation followed by geographic ulcers (20%). Negative 
viral swabs were predominantly obtained from cases with subepithelial inflammation 
(13 of 14, 93%). Only in one (7%) case with an epithelial inflammation, presenting with 
table 1. Characteristics of infectious keratitis patients enrolled in this study.
HIV infected
(n=28)
HIV uninfected
(n=18)
crude odds ratio
(95% cI) P-value
Gender
Female 22 (76) 7 (24) 5.8 (1.6–21.3) 0.01
Male 6 (35) 11 (65)
Age in years 38 (31–45) 52 (27–72) na 0.19
Ethnicity
Sotho 19 (66) 10 (34) 1.7 (0.5–5.7) 0.53
Shangaan 9 (53) 8 (47)
Low educational status 10 (36) 9 (50) 0.6 (0.2–1.9) 0.37
Low financial income 22 (79) 14 (78) 1.0 (0.3–4.4) 1.00
CD4 cell count in cells/mm³ 254 (162–353) Na na na
Days between onset of eye complaints and 
presentation
18 (11–49) 23 (9–38) na 0.93
Referred from primary healthcare facility 18 (64) 8 (44) 2.3 (0.7–7.5) 0.23
Use of topical antibiotics prior enrolment 10 (36) 4 (22) 1.9 (0.5–7.5) 0.51
Diagnosis (clinical and laboratory data combined)
Viral keratitis (n=15) 10 (67) 5 (33) 3.7 (1.1–13.3)a 0.06
Viral and bacterial keratitis (n=14) 11 (79) 3 (21)
Bacterial keratitis (n=17) 7 (41) 10 (59)
Data are shown as number (%) or median (interquartile range). CI, Confidence interval; P-value, Pearson 
Chi-square or Mann-Whitney U test; na, not applicable; HIV, human immunodeficiency virus.
aCrude odds ratio and P-value were calculated for viral keratitis (including viral and bacterial keratitis) vs. 
bacterial keratitis.
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table 2. Aetiology of infectious keratitis defined by clinical and laboratory diagnostic methods.
HSV-1
PcrPOS
VZV
PcrPOS
microbial culture positive
HIV infected patients (n=28):
  Viral keratitis (n=10)
Laboratory confirmed diagnosis 
(n=4)
n=2 n=2 No bacterium cultured
Clinical diagnosis only (n=6) None None No bacterium cultured
  Viral and bacterial keratitis (n=11)
Laboratory confirmed diagnosis 
(n=8)
n=1 n=7 Staphylococcus epidermidis (n=3)
Staphylococcus aureus (n=2a)
Bacillus species (n=1)
Stenotrophomonas maltophilia (n=1)
Staphylococcus epidermidis and Escheria coli (n=1)
Clinical diagnosis only (n=3) None None Staphylococcus capitis (n=1)
Staphylococcus epidermidis (n=1)
Enterobacter cloacae (n=1)
  bacterial keratitis (n=7)b
Laboratory confirmed diagnosis 
(n=7)
None None Staphylococcus epidermidis (n=2)
Pseudomonas aeruginosa (n=2)
Staphylococcus capitis (n=1)
Staphylococcus aureus and Streptococcus viridans (n=1)
Corynebacterium, Enterococcus faecalis, Escheria coli 
and Candida albicans (n=1)
Clinical diagnosis only (n=0) None None No bacterium cultured
HIV uninfected patients (n=18):
  Viral keratitis (n=5)
Laboratory confirmed diagnosis 
(n=2)
n=2 None No bacterium cultured
Clinical diagnosis only (n=3) None None No bacterium cultured
  Viral and bacterial keratitis (n=3)
Laboratory confirmed diagnosis 
(n=1)
None n=1 Staphylococcus aureus and Proteus mirabilis (n=1)
Clinical diagnosis only (n=2) None None Staphylococcus epidermidis (n=1)
Staphylococcus capitis and Acinetobacter haemolyticus 
(n=1)
  bacterial keratitis (n=10)
Laboratory confirmed diagnosis 
(n=8)
None n=1c Staphylococcus epidermidis (n=4)
Staphylococcus aureus (n=1)
Pseudomonas aeruginosa (n=1)
Staphylococcus epidermidis and Proteus mirabilis (n=1)
Streptococcus viridans and Haemophilus influenza (n=1)
Clinical diagnosis only (n=2) None None No growth in culture (n=2)
HIV, human immunodeficiency virus; HSV-1, herpes simplex virus type 1; VZV, varicella zoster virus.
aHSV-1 DNA was detected in combination with Staphylococcus aureus
bOne viral corneal swab was unavailable after transport.
cVascular leakage of VZV DNA from extensive corneal neovascularisation most likely resulted in detection 
of VZV DNA.
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a dendritic lesion typical for HSV-1 epithelial keratitis, no viral DNA could be detected. 
Notably, subepithelial inflammation was significantly associated with higher median 
PCR Ct values [median of 38.2 (IQR 37.4–39.1)] for subepithelial inflammation vs. 32.6 
(IQR 26.7–35.0) for epithelial inflammation, P=0.005). Furthermore, viral DNA negative 
swabs were significantly associated with an increased duration of symptoms [median of 
37 (IQR 23–92)] days for cases with DNA negative swabs vs. 14 (IQR 6–18) days for cases 
with DNA positive swabs, P=0.003). A reported history of herpes zoster ophthalmicus 
(OR=46.9, 95% CI 7.4–287.6; P<0.001) was associated with a viral aetiology of keratitis 
and a trend between viral aetiology and HIV infection (OR=3.7, 95% CI 1.1–13.3; P=0.06) 
was also observed. Among viral keratitis cases, a bacterial superinfection was associated 
with lower CD4 cell counts [median of 168 (IQR 92–322)] cells/mm³ for viral keratitis with 
bacterial superinfection vs. 312 (IQR 212–490) cells/mm³ for viral keratitis, P<0.05).
Twenty-one (47%) keratitis cases were complicated by anterior uveitis of which 18 
(86%) were viral keratitis (table 3). Viral DNA was detected in corneal swabs of 11 of 18 
(61%) keratouveitis patients: VZV (n=10) and HSV-1 (n=1). Keratouveitis cases were sig-
nificantly more common among HIV-infected than HIV-uninfected individuals (OR=16.9, 
95% CI 3.2–89.7, P<0.001), among patients with an intraocular pressure of >21 mmHg 
table 3. Factors associated with the development of uveitis in infectious keratitis patients.
uveitis present
(n=21)
uveitis absent
(n=25)
crude odds ratio
(95% cI) P-value
Gender
Female 16 (55) 13 (45) 3.0 (0.8–10.6) 0.13
Male 5 (30) 12 (70)
Age in years 38 (32–49) 41 (30–62) na 0.68
Low educational status 10 (53) 9 (47) 1.6 (0.5–5.3) 0.55
Low financial income 18 (86) 18 (72) 2.3 (0.5–10.5) 0.26
HIV infected 19 (91) 9 (36) 16.9 (3.2–89.7) <0.001
CD4 cell count in cells/mm³ 226 (137–332) 343 (194–427) na 0.09
Days between onset of eye complaints and 
presentation
18 (11–45) 24 (9–39) na 0.97
Intraocular pressure of >21 mmHg 7 (33) 2 (9)a 5.0 (0.9–27.7) 0.05
Diagnosis (clinical and laboratory data combined)
Viral keratitis (n=15) 7 (47) 8 (53) 7.6 (1.8–32.7)b 0.005
Viral and bacterial keratitis (n=14) 11 (79) 3 (24)
Bacterial keratitis (n=17) 3 (18) 14 (82)
Data are shown as number (%) or median (interquartile range). CI, Confidence interval; P-value, Pearson 
Chi-square or Mann-Whitney U test; na, not applicable; HIV, human immunodeficiency virus.
aThree keratitis patients without uveitis had no recorded intraocular pressure.
bCrude odds ratio and P-value were calculated for viral keratitis (including viral and bacterial keratitis) vs. 
bacterial keratitis.
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than ≤21 mmHg (OR=5.0, 95% CI 0.9–27.7; P=0.05) and among viral than bacterial aetiol-
ogy (OR=7.6, 95% CI 1.8–32.7; P=0.005). Also, a trend between lower CD4 cell counts and 
uveitis was observed among those with HIV-infection [median of 226 (IQR 137–332)] 
cells/mm³ for keratouveitis vs. 343 (IQR 194–427) cells/mm³ for keratitis, P=0.09).
clinical outcome of disease
Follow-up after treatment initiation was poor. Thirty-four of 46 (74%) patients had one 
or more follow-up visits and the median follow-up time was 7 (IQR 7–28) days. The 
affected eye was visually impaired at the last follow-up visit after treatment initiation 
in 17 of 34 (50%) patients of which 8 (47%) were blind. Severe visual impairment and 
blindness was significantly associated with increased duration of symptoms [median 
of 36 (IQR 20–112)] days for severe visual impairment and blindness vs. 14 (IQR 6–37) 
days for no severe visual impairment and blindness (P=0.02). Adjusting for duration of 
symptoms, no demographic or clinical characteristics were associated with severe visual 
impairment and blindness (data not shown). Notably, a bacterial superinfection in viral 
keratitis patients was not associated with poorer outcome after treatment.
DIScuSSIOn
This study reports on the clinical and corneal microbial profile come of infectious 
keratitis in patients presenting to the ophthalmology outpatient department of three 
hospitals in a high HIV prevalence setting in rural South Africa. The data implicate that 
corneal herpesvirus infections, in part complicated by bacterial superinfection and/or 
uveitis, are relatively more frequently associated with infectious keratitis in HIV-infected 
individuals with pronounced visual morbidity. A significant association between HIV 
infection and keratouveitis was noted, suggesting its potential use as clinical marker to 
prompt investigation of the patient’s HIV status.
The observed high frequency of viral aetiology of infectious keratitis in our study has 
not been described before in sub-Saharan Africa and is higher than observations in simi-
lar studies from Australia and China [2, 15]. The major role of herpesviruses might be due 
to the high HIV prevalence, because a trend was observed between HIV-infection and 
viral keratitis. Our data are in line with observations reporting increased susceptibility of 
HIV-infected individuals to viral keratitis [7]. We identified VZV as the most prevalent viral 
cause of infectious keratitis in our study population. This contrasts previous studies from 
sub-Saharan Africa and high-resource countries that report a predominant role of HSV-1 
causing viral keratitis [5-6, 16]. The important role of VZV in our study might be due to 
the high HIV prevalence as HIV-infected individuals are at higher risk for VZV keratitis 
than for HSV-1 keratitis [7, 17]. Unfortunately, previous studies from sub-Saharan Africa 
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did not report on the patients’ HIV status [5-6]. Reasons for the observed minor role of 
HSV-1 in our study remain unclear as seroprevalence of HSV-1 among HIV-infected ART 
naïve individuals in our setting is very high (98%) [18]. Adenovirus was not detected in 
our study, which contrasts earlier studies performed in high-resource settings where 
adenovirus is identified as an important causative pathogen of keratoconjunctivitis 
[19]. Studies from sub-Saharan Africa are not available, but our results may suggest that 
geographical factors play a role in the different pathogen distribution observed.
The distribution of bacterial pathogens, largely Gram-positive bacteria, confirms 
observations in other studies from sub-Saharan Africa [8, 20]. Bacteria were detected in 
almost half of the viral keratitis cases and bacterial superinfection was associated with 
lower CD4 cell count. Although limited data are available on the clinical consequences 
of bacterial superinfections in viral keratitis, bacterial superinfections may worsen visual 
outcome of HSV keratitis if appropriate treatment is delayed [21]. In our study, however, 
poorer visual outcome after treatment was not associated with bacterial superinfection. 
A fungus (Candida albicans) was detected in only one patient diagnosed with bacte-
rial keratitis. This is in sharp contrast to similar studies from Ghana and Tanzania that 
reported fungi as the causative pathogen in up to 50% of keratitis cases of keratitis 
[22-23]. This may be due to the exclusion of traumatic keratitis as trauma is one of the 
most important risk factors for fungal keratitis or due to the geographical differences as 
fungal keratitis is more likely to occur toward tropical latitudes [2-3].
PCR analyses of corneal swabs supported the clinical observation of viral keratitis in 
cases with epithelial inflammation. In cases with subepithelial inflammation, however, 
detection of viral DNA was often negative and, if positive just above the detection limit 
of the qPCR. This is in line with a study that observed a lower percentage of keratitis 
cases with positive HSV-1 DNA in patients with subepithelial inflammation compared 
to patients with epithelial inflammation [24]. Furthermore, increased disease duration 
was associated with a negative viral swab in cases with a clinical viral keratitis diagnosis.
Anterior uveitis was an important complication of infectious keratitis in our study, in 
particular in cases of viral aetiology and among HIV-infected individuals. This poses a 
challenge as management of keratouveitis requires specialized treatment. The associa-
tion between HIV infection and the development of anterior uveitis, combined with the 
observed trend between immunodeficiency and anterior uveitis, suggest that cell-
mediated immunity plays an important role controlling corneal infection [25-26]. Also, 
the presence of anterior uveitis might be used as a pointer of HIV infection that indicates 
the need of HIV counselling and testing in patients presenting with this condition.
The visual outcome at last follow-up visit after treatment of infectious keratitis 
observed in our study was poor and associated with increased duration of symptoms 
which confirms observations from a study from Tanzania addressing visual outcome in 
infectious keratitis [8]. Unfortunately, we did not collect data to determine reasons for 
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this delay, but both patient- and healthcare system-associated factors may have played 
a role. A potential contributing factor to the poor visual outcome observed, is initial mis-
management at PHC level as none of the referred patients from PHC facilities received 
topical antiviral and/or adequate antibiotic treatment.
A limitation to this study is the small sample size which might have resulted in an 
overestimation of the relationships found. Follow-up studies on larger number of 
keratitis patients from rural settings with high HIV prevalence are warranted to validate 
the trends found in this study. Also, we included patients at the outpatient department 
of hospitals and not at PHC facilities, which may have resulted in some degree of bias 
towards viral keratitis as potential bacterial keratitis cases were more likely treated suc-
cessfully at PHC level. In addition, as we excluded patients with traumatic keratitis and 
contact lens wearers it is likely that there is some degree of bias towards viral keratitis as 
these are important predisposing factors for microbial keratitis [2]. However, we expect 
the degree of this bias to be limited as we excluded only two keratitis cases due to 
trauma and none for the use of contact lenses.
In conclusion, the results of this study implicate that herpetic keratitis, in part com-
plicated by bacterial superinfection and/or uveitis, is relatively more common among 
HIV-infected individuals presenting with infectious keratitis in rural South Africa. This 
warrants an increase of the awareness among healthcare workers in these settings for 
early clinical signs of herpetic keratitis and prompt initiation of antiviral treatment in 
these cases to prevent blindness. Moreover, the significant association between HIV 
infection and keratouveitis warrants examination of the patient’s HIV status.
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AbStrAct
Objectives. To describe the spectrum of ocular complications of herpes zoster ophthal-
micus (HZO) in rural South Africa.
methods. Patients presenting with visual complaints and active or healed HZO at the 
ophthalmology outpatient department of three hospitals in rural South Africa were 
included in this study. Demographic and clinical data were collected and HIV status was 
determined for all participants.
results. Forty-eight patients were included and the majority (81%) were HIV-infected. 
Poor vision was reported by 94% of patients, painful eye by 79% and photophobia by 
63%. A diverse spectrum of ocular complications was observed with corneal inflamma-
tion and opacification as the most frequent (77%) followed by anterior uveitis (65%). The 
majority of patients (65%) presented with late stage ocular complications associated 
with irreversible loss of vision whereas early stage complications, such as punctate 
epithelial keratitis and anterior uveitis were less common. Blindness of the affected eye 
was observed in 68% of patients with late stage complications. There was a consider-
able delay between onset of symptoms and first presentation to the ophthalmology 
outpatient department (median time 35 days; range 1-2500 days) and longer delay was 
associated with late stage ocular complications (P=0.02).
conclusions. HZO patients present with relatively late stage ocular complications and 
blindness among these patients is common. The delayed presentation to the ophthal-
mology outpatient department of hospitals in our rural setting is of concern and efforts 
to improve this situation are of paramount importance to improve ocular outcomes 
of HZO.
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IntrODuctIOn
Herpes zoster ophthalmicus (HZO) is the clinical manifestation of reactivation of latent 
varicella-zoster virus (VZV) infection located within the ophthalmic branch of the 
trigeminal nerve [1-4]. Due to impaired cell-mediated immunity, human immunodefi-
ciency virus (HIV)-infected individuals are at increased risk of developing HZO (relative 
incident risk of 6.6) compared to HIV-uninfected individuals [5-8]. If cutaneous HZO is left 
untreated, ocular involvement occurs in more than half of patients and leads to chronic 
debilitating pain, visual impairment and eventually (unilateral) blindness [1-3, 9]. These 
ocular complications are more common among HIV-infected individuals and have a 
more severe clinical presentation and higher recurrence rate, especially in individuals 
with low CD4 count [1, 3, 6, 8].
The spectrum of ocular complications of HZO is diverse. Corneal inflammation and 
opacification (49-89%) and anterior uveitis (43-92%) are the most common complica-
tions, but ocular cranial-nerve palsies, neuralgia, eyelid deformities, (blepharo-)conjunc-
tivitis, (epi-)scleritis and optic neuritis may also occur [1-4, 7, 9-13]. In the acute phase of 
HZO ‘early’ corneal complications are may develop such as punctate epithelial keratitis 
and dendritic keratitis; these are associated with minimal risk of visual impairment. 
However, if left untreated, progression to chronic, late-stage corneal complications with 
serious visual impairment due to corneal opacification and ulceration may develop 
[1, 3]. Additionally, in cases where uveitis occurs, mild HZO-associated acute anterior 
uveitis may progress to sight-threatening stages due to chronic inflammation leading 
to corneal oedema, iris atrophy, posterior synechiae and cataract formation [3, 7]. Thus, 
early recognition of ocular involvement in HZO patients and subsequent initiation of 
targeted oral and topical treatment is essential to prevent ocular morbidity.
South Africa is highly affected by the HIV epidemic and the clinical presentation of 
dermal HZO is relatively common [14]. Data on ocular manifestations of HZO in HIV-
infected sub-Saharan Africans are scarce [9, 14-15]. The aim of this study was to describe 
the spectrum of ocular complications of HZO and, in particular, to distinguish between 
early and late stage ocular complications as these impact on visual prognosis.
mAtErIAl AnD mEtHODS
Study setting and population
This study was conducted at the ophthalmology outpatient department of three hos-
pitals in rural South Africa (Mopani District) and is a sub-analysis of data collected in 
Anova’s Mopani Eye Project. Briefly, this project aimed to improve eye care through a 
combination of clinical research and health systems strengthening activities. For this 
Chapter 4
72
analyses, cases were selected from three ongoing clinical studies initiated with the fol-
lowing objectives: to determine the (1) aetiology of uveitis, (2) aetiology of infectious 
keratitis and (3) impact of HIV infection and antiretroviral therapy (ART) on the eye 
(Schaftenaar E, Mopani Eye Project 2015, unpublished data). Adults (≥18 years old) with 
a clinical diagnosis of uveitis or infectious keratitis were included in the first two studies 
and adults with documented HIV infection, regardless presence of eye complaints, were 
included in the third study. Individuals presenting in either of these studies with active 
or healed HZO were included in the current analysis.
HZO diagnosis was defined as presence of a primary vesiculomacular and dysesthetic 
skin rash or typical scar (with matching clinical history of HZO) within the ophthalmic 
dermatome [7, 16]. Demographic and clinical data were collected at enrolment in all 
three studies. Each participant had a full ophthalmic examination, including measure-
ment of visual acuity, slit-lamp examination and dilated indirect ophthalmoscopy. Visual 
acuity testing was performed using an “illiterate E” Snellen chart at a distance of 6 meter 
and visual acuity was defined as the lowest line value where at least half the letters were 
correctly identified by the participant without correction of the affected eye. If visual 
acuity was <6/60, the distance between the Snellen chart and patient was reduced to 3 
or 1 meter. If visual acuity was <1/60, “hand movements”, “light perception” or “no light 
perception” was recorded. Visual impairment was defined according to the International 
Classification of Diseases (ICD-10, version 2010) on basis of the individual’s visual acuity 
[17]. The studies were approved by the Human Research Ethics Committee (University of 
the Witwatersrand; Johannesburg, South Africa) and written informed consent (includ-
ing ocular photography) was obtained from all participants.
classification of early and late ocular complications
Ocular complications were classified as “early” or “late” based on stage of disease pro-
gression and (potential) restoration of normal vision. The following manifestations were 
classified as early stage: eyelid oedema, (blepharo-)conjunctivitis, (epi-)scleritis, punc-
tate epithelial keratitis, pseudodendritic or dendritic keratitis, nummular keratitis and/
or anterior uveitis [7]. Late stage ocular complications were in case of eyelid scarring, 
trichiasis, entropion, ptosis, deep stromal keratitis, disciform keratitis, corneal ulceration, 
neurotrophic keratopathy, necrotising retinitis, retinal detachment and optic neuritis. 
Although necrotising retinitis and optic neuritis may also occur in the early phase, we 
decided to include both as late stage ocular complications due to their devastating ef-
fect on visual acuity [7].
Data analysis
Data were double-entered and validated using EPI-INFO version 3.5.4 (Centers for Dis-
ease Control; Atlanta, GA) and analysed using IBM SPSS Statistics version 22 (IBM; New 
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York City, NY). Description of study population, clinical and laboratory findings were 
performed using number with proportion and median with range. Comparison was 
done by Chi-squared tests with Fisher’s Exact if appropriate for categorical variables 
and Mann-Whitney for continuous variables. Data are presented as odds ratio (OR) 
with 95% confidence interval (CI), mean with standard deviation (SD) or as median 
with range.
rESultS
The study sample (n=48) consisted of 10 (21%) men and 38 (79%) women with a median 
age of 40 years (range 18-72 years). Thirty-nine (81%) individuals were HIV-infected, 
with a median CD4 count of 260 cells/mm³ (range 43-813 cells/mm³), of which 25 (64%) 
received ART. Most cases (n=39; 81%) presented with healed (no active skin lesions) and 
9 patients (19%) with active HZO. HZO was unilateral except for two cases. Median days 
between reported onset of eye complaints and first presentation to the ophthalmology 
outpatient department was 35 days (range 1-2500 days).
Poor vision (94%) was the most common ocular symptom, followed by a painful eye 
(79%) and photophobia (63%). A diverse spectrum of ocular HZO complications was 
observed (figure 1), with corneal inflammation and opacification (77%) as the most 
common ocular complication followed by anterior uveitis (65%) (table 1). Intraocular 
complications were more common among HIV-infected than HIV-uninfected individuals 
(OR=5.8; 95% CI: 1.2–27.6, P<0.05). Scleritis, cranial nerve palsy and optic neuritis was 
not observed. The majority (n=31; 65%) of patients presented with late stage ocular 
complications. These patients reported longer time between onset of eye symptoms and 
presentation to the ophthalmology outpatient department (median of 18 vs. 46 days; 
P=0.02) and presented more frequently with healed than active HZO (OR=5.1; 95% CI: 
1.1–24.0, P=0.05) than those with early stage complications (table 2). However, among 
individuals presenting with healed HZO, early ocular complications were observed in 
only 11 (28%) patients and late stage ocular complications were observed in three (33%) 
patients with active HZO. Visual impairment (81%), including blindness (23 of 39 indi-
viduals; 59%), was common and late stage ocular complications were associated with 
blindness of the affected eye (OR=15.8; 95% CI: 3.0–82.5, P<0.001).
DIScuSSIOn
This study reports on the early and late stage ocular complications of HZO patients pre-
senting to the ophthalmology outpatient department of three hospitals in rural South 
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Africa. A diverse spectrum of ocular HZO complications was observed. Most patients had 
late stage ocular complications, which was associated with blindness of the affected eye.
Corneal inflammation and opacification were the most common complication fol-
lowed by anterior uveitis. This observation is in line with previous studies from Africa 
and the Unites States [9, 11-12]. Intraocular complications were more common among 
table 1. Distribution of ocular complications of herpes zoster ophthalmicus by HIV status.
HIV-infected
(n=39)
HIV-uninfected (n=9) total (n=48)
Eyelid and conjunctiva
Eyelid oedema 7 (18) 3 (33) 10 (21)
Eyelid scarring 10 (26) 0 (0) 10 (21)
Eyelid trichiasis 2 (5) 0 (0) 2 (4)
Entropion 1 (3) 0 (0) 1 (2)
Ptosis 8 (21) 0 (0) 8 (17)
Blepharoconjunctivitis 5 (13) 2 (22) 7 (15)
Conjunctivitis 13 (33) 3 (33) 16 (33)
Episclera and sclera
Episcleritis 3 (8) 0 (0) 3 (6)
Scleritis 0 (0) 0 (0) 0 (0)
cornea
Corneal inflammation and opacification 29 (74) 8 (89) 37 (77)
Punctate epithelial keratitis 8 (21) 7 (78) 15 (31)
Pseudo dendritic keratitis 3 (8) 0 (0) 3 (6)
Dendritic keratitis 2 (5) 3 (33) 5 (10)
Nummular keratitis 4 (10) 0 (0) 4 (8)
Stromal keratitis 7 (18) 3 (33) 10 (21)
Disciform keratitis 3 (8) 1 (11) 4 (8)
Corneal ulceration 4 (10) 2 (22) 6 (13)
Neurotrophic keratopathy 14 (36) 3 (33) 17 (35)
Abnormal corneal sensation 12 (31) 2 (22) 14 (29)
Anterior chamber
Anterior uveitis 28 (72) 3 (33) 31 (65)
Keratouveitis 17 (44) 2 (22) 19 (40)
Posterior synechiae 11 (28) 2 (22) 13 (27)
Posterior segment
Posterior involvement 4 (10) 0 (0) 4 (8)
Necrotising retinitis 3 (8) 0 (0) 3 (6)
Retinal detachment 2 (5) 0 (0) 2 (4)
Optic neuritis 0 (0) 0 (0) 0 (0)
Data are shown as numbers (%). HIV, human immunodeficiency virus.
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HIV-infected than HIV-uninfected individuals. HIV-related immunodeficiency might lead 
to rapid breach of the corneal defence mechanisms resulting in intraocular inflamma-
tion in case of VZV-infection, which is in line with previous studies in which HIV infection 
was associated with more severe ocular disease in HZO [1, 3, 6, 8]. At enrolment we 
table 2. Early versus late stage ocular complications of herpes zoster ophthalmicus.
Early stage ocular
complications
(n=17)
late stage ocular
complications
(n=31)
crude odds
ratio
(95% cI)
P-value
Age in years 40 (24-72) 40 (18-71) na 0.470
Gender
Male 4 (40) 6 (60) 1.3 (0.3–5.4) 0.727
Female 13 (34) 25 (66)
HIV-status
HIV-infected 14 (36) 25 (64) 1.1 (0.2–5.2) 1.000
HIV-uninfected 3 (33) 6 (67)
CD4 cell count in cells/mm³ 301 (32-813) 244 (52-670) Na 0.598
HZO
Active HZO 6 (67) 3 (33) 5.1 (1.1–24.0)a 0.051
HIV-infected 3 3
HIV-uninfected 3 0
Healed HZO 11 (28) 28 (72)
HIV-infected 11 22
HIV-uninfected 0 6
Time between onset of eye complaints 
and presentation to the ophthalmology 
outpatient department
18 (1-131) 46 (2-2500) Na 0.016
Reported ocular symptom
Poor vision 14 (82%) 31 (100%) – 0.039
Painful eye 17 (100%) 21 (68%) – 0.009
Photophobia 15 (48%) 15 (88%) 8.0 (1.6–41.0) 0.006
Visual acuity of the affected eye
≥ 6/18 9 (100) 0 (0) 15.8 (3.0–82.5)b <0.001
< 6/18 but ≥ 6/60 5 (36) 9 (64)
< 6/60 but ≥ 3/60 1 (50) 1 (50)
< 3/60 2 (9) 21 (91)
Data are shown as numbers (%) or median (range). HIV, human immunodeficiency virus; HZO, herpes zoster 
ophthalmicus; CI, Confidence interval; P-value, Pearson Chi-square or Mann–Whitney U test; na, not ap-
plicable.
aCrude odds ratio and P-value were calculated for active HZO vs. healed HZO between early and late stage 
ocular complications.
bCrude odds ratio and P-value were calculated for visual acuity ≥ 3/60 vs. < 3/60 between early and late 
stage ocular complications.
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observed a significant rate of visual disability and blindness (81%). Although we did 
not report on visual acuity after HZO-specific treatment, we expect the final rate of 
visual disability and blindness to be high since the majority presented with late stage 
manifestations associated with often irreversible visual impairment and blindness [1, 3, 
7]. The observed high rate of visual disability was similar to two previous studies from 
Africa twenty years ago [9, 15].
There was a considerable delay (median time of 35 days) between onset of symptoms 
and first presentation to the ophthalmology outpatient department; such delay was 
associated with late stage ocular complications. The association between delay to the 
ophthalmology outpatient department and late stage complications might be due to 
delayed initiation of antiviral treatment as early initiation thereof (≤72 hours after onset 
of rash) reduces the risk of progression to late stage ocular complications [3, 18]. The 
delay observed in our study is long and much higher than reported by a similar study 
conducted at the ophthalmology outpatient department of the Groote Schuur Hospital 
(Cape Town, South Africa) in which a median delay of 5 days was reported [14]. Both 
patient- and healthcare system-associated factors may have contributed to this dis-
crepancy. First, patient delays are generally more common in rural (e.g. Mopani District) 
than urban (e.g. Cape Town) South African settings. To our knowledge no studies have 
reported on patient delay in case of HZO or eye complaints, but substantial delays have 
been reported for other conditions between such settings [19-20]. Second, healthcare 
system delays are likely to occur, especially in rural settings where ophthalmological 
expertise and resources are limited and the referral process for ophthalmologic ex-
amination is complicated. Unfortunately, we did not record if individuals visited primary 
healthcare facilities before presenting to our ophthalmology outpatient departments.
Healed HZO was associated with late stage ocular complications. However, seem-
ingly contradictory, early ocular complications were observed in 11 (28%) patients, all of 
whom were HIV-infected, presenting with healed HZO. Although no demographic and 
clinical characteristics, including CD4 count, were associated with these 11 patients, the 
early stage ocular complications observed in these healed HZO patients may be due 
to higher frequency of local (e.g. corneal) recrudescence of VZV due to HIV-induced 
immune senescence [5-8]. Also, late stage ocular complications were observed in three 
(33%) HIV-infected patients with active HZO. Since HIV infection is associated with more 
severe ocular disease in HZO, these three patients may have developed late stage ocular 
complications early after onset of disease [1, 3, 6, 8]. Most HZO patients included in our 
study were HIV infected and were significant younger than HIV-uninfected individuals. 
This is in agreement with previous HZO studies from sub-Saharan Africa [9, 12, 14]. 
Among the HIV-infected individuals, four (10%) HZO patients were tested reactive for 
HIV for the first time as they were offered provided-initiated HIV testing based on their 
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clinical presentation. This highlights the importance of providing HIV testing to indi-
viduals presenting with HZO as advocated in previous studies [1, 8, 10, 21-22].
A potential limitation is the study design whereby potential HZO patients were se-
lected from three different clinical studies. However, selection bias is unlikely, because 
any individual with HZO presenting with ocular complaints was eligible for participation 
in one of our studies. Due to selection of individuals with ocular HZO complications, 
no inferences could be made about the prevalence of ocular HZO complications in 
the general population of the Mopani District. Finally, because diagnosis was solely 
based on the patient’s history and clinical characteristics, not all observed ocular HZO 
complications may be caused directly by VZV as involvement of other viruses or even 
an ocular bacterial superinfection are optional. However, the latter is unlikely because 
the sensitivity and specificity of the clinical characteristics in combination with active or 
healed HZO lesions are very disease-specific [16, 23].
In this study, we demonstrated that HZO patients presenting to the ophthalmology 
outpatient department of three hospitals in rural South Africa have relatively late stage 
ocular complications and that this is associated with serious visual impairment and 
blindness. This emphasizes the importance of early recognition of ocular involvement in 
HZO and subsequent initiation of appropriate antiviral treatment at primary healthcare 
level with prompt referral to hospitals with ophthalmology departments to reduce these 
sight-threatening ocular complications. As such, appropriate antiviral treatment should 
be available at primary healthcare level, even in rural settings. Furthermore, to prevent 
HZO-associated ocular morbidity, development of clinical guidelines and training pro-
grammes for healthcare workers as well as health system strengthening and community 
awareness are of paramount importance. These efforts will improve prevention and 
clinical management of ocular HZO complications and reduce the burden of avoidable 
visual impairment and blindness in South Africa.
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AbStrAct
Aims. To determine the burden of disease in a unique sample of uveitis patients from a 
rural South African setting
methods. Data in this cross-sectional study were collected from patients presenting 
with uveitis (n=103) at the ophthalmology outpatient department of three hospitals in 
rural South Africa. Demographic and clinical data were collected and laboratory analysis 
of aqueous humour, serological evaluation and routine diagnostics for tuberculosis 
were performed.
results. Sixty-six (64%) participants were HIV-infected. Uveitis was predominantly of 
infectious origin (72%) followed by idiopathic (16%) and autoimmune (12%). Infectious 
uveitis was attributed to herpesvirus (51%), Mycobacterium tuberculosis (24%) and Trepo-
nema pallidum (7%) infection. HIV-infected individuals were more likely to have infec-
tious aetiology of uveitis compared to HIV-uninfected individuals (83 vs. 51%; P=0.001).
conclusion. Microbial aetiology of uveitis is common in areas where HIV and TB are 
endemic. In these settings, a high index of suspicion for infectious origin of uveitis is 
warranted.
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IntrODuctIOn
Uveitis is a potential sight-threatening eye condition responsible for up to 25% of all 
blindness in the developing world [1]. Aetiology is diverse, includes infectious and 
non-infectious disorders (e.g. autoimmune uveitis), and differs geographically due to 
host and environmental factors [1-2]. In developed countries uveitis is mostly attributed 
to non-infectious causes. Data from the African continent are limited, but suggest that 
infectious diseases play an important role in uveitis [1]. The human immunodeficiency 
virus (HIV) epidemic impacts greatly on the burden of uveitis in this region. HIV-infected 
individuals have an increased risk of uveitis, in particular of infectious aetiology, and 
experience more severe disease [1, 3-4]. Furthermore, the influence of the high tubercu-
losis (TB) prevalence in this region on uveitis aetiology is unknown.
Early diagnosis and initiation of treatment of uveitis is crucial for good visual outcome, 
especially in infectious uveitis, and poses a challenge in resource- and ophthalmic skills-
constraint settings [3]. Hence, identification of the most likely aetiology and risk factors 
associated with aetiology are of paramount importance to diagnose and treat uveitis 
effectively. Available data of uveitis aetiology obtained in developed countries cannot 
be extrapolated to an African setting due to differences in population age distribution, 
immunogenetic make-up and ongoing HIV and TB epidemics. Herein, we characterized 
the burden of uveitis in a rural South African setting with a high HIV and TB prevalence.
mAtErIAl AnD mEtHODS
Study population and setting
This cross-sectional study was conducted at the ophthalmology outpatient department 
of three hospitals in rural South Africa (Mopani District) from September 2013 to May 
2015. Criteria for participation were adult age (≥18 years old), no recent history of ocular 
surgery or trauma and a diagnosis of uveitis based on observations during slit-lamp and 
funduscopic examination: keratic precipitates, flare and/or cells in the anterior chamber, 
flare/haze and/or cells in the vitreous and/or signs of choroiditis, retinitis or retinal 
vasculitis [2]. Participants had to be willing to test for HIV. This study was approved pro-
spectively by the Human Research Ethics Committee (University of the Witwatersrand; 
Johannesburg, South Africa; M130202). Written informed consent was obtained from all 
participants.
Study procedures
Demographic and clinical data were collected from 103 uveitis patients and full ophthal-
mic examination performed, including visual acuity using an “illiterate E” Snellen chart at 
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a distance of 6 meters, slit lamp examination, intraocular pressure using the Icare TA01i 
(Icare Finland Oy; Helsinki, Finland) and dilated indirect funduscopy. Photographs were 
taken of the anterior and posterior segment using an Apple I-phone 4S on a slit-lamp 
adapter and an Optomed Smartscope M5, respectively. Visual impairment was defined 
according to the International Classification of Diseases [5].
Blood was drawn for serological analysis for Treponema pallidum by Treponemal 
(automated T. pallidum-specific chemi-luminescence immunoassay and fluorescent 
treponemal antibody absorption test) and non-Treponemal (Venereal Disease Research 
Laboratory) tests. Sputum examination for Mycobacterium tuberculosis was conducted 
using the Xpert MTB/RIF assay (Cepheid Inc.; Sunnyvale, CA) in individuals with produc-
tive cough and chest X-ray was done in participants suspected of TB. In participants with 
severe visual impairment diagnostic aspiration of aqueous humour (AH) was performed. 
Goldmann-Witmer coefficient (GWC) for the detection of pathogen-specific intraocular 
antibody production and PCR detection of viral DNA in ocular fluid was performed for 
herpes simplex virus type 1 (HSV-1) and 2 (HSV-2), varicella zoster virus (VZV), Epstein-
Barr virus (EBV) and cytomegalovirus (CMV) to support diagnosis. A virus-specific GWC 
>3 of AH samples was considered indicative for intra-ocular local antibody production 
[6-7].
Data analysis
Data were double-entered using EPI-INFO version 3.5.4 (Centers for Disease Control; 
Atlanta, GA) and analysed using IBM SPSS Statistics version 22 (IBM; New York City, NY). 
Presumptive aetiology of uveitis, including infectious vs. non-infectious origin, was 
based on the combination of patient’s history, clinical characteristics and laboratory 
data including analysis of ocular fluid, serological evaluation and sputum and chest 
X-ray examination. All clinical findings observed during slit-lamp and funduscopic 
examination were reviewed by a team of uveitis specialists (ES, CM, SB) using the pho-
tographs of anterior and posterior segment of the eye. Data were compared between 
participants with infectious and non-infectious uveitis by Chi-squared test, with Fisher’s 
Exact if appropriate, for categorical variables and Mann-Whitney-Wilcoxon U test for 
continuous variables. Variables with P-values <0.10 in univariate analysis and age as 
potential confounder were included in multivariate analysis using logistic regression 
(forward Likelihood Ratio).
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rESultS
Demographics and clinical presentation of study population
We recruited 103 uveitis patients with median age of 42 (range 19–83) years including 
66 (64%) women. Sixty-six (64%) patients were HIV-infected of which 41 (62%) received 
antiretroviral therapy (ART). In the latter group and ART-naïve patients the median CD4 
count was 226 (range 9–831) and 260 (range 52–813) CD4 T-cells/mm³, respectively. The 
most common symptoms reported were eye pain (91%), poor vision (86%), photophobia 
(86%) and tearing (61%). Median disease duration was 14 (range 1–296) days. Seventy-
two (71%) patients presented with anterior uveitis, 15 (15%) with intermediate uveitis 
and 13 (13%) with posterior uveitis. Panuveitis was observed in only two patients.
Aetiology of uveitis
Uveitis was diagnosed as infectious in 74 (72%, 95% CI: 63–82%), idiopathic in 17 (16%, 
95% CI: 10–24%) and autoimmune in 12 patients (12%, 95% CI: 6–18%). The group of 
autoimmune uveitis includes 2 patients (17%) with presumed sarcoidosis-associated 
uveitis, 2 (17%) patients with Fuchs’ heterochromic uveitis and 1 (8%) patient with 
scleritis-associated uveitis (figure 1). Infectious uveitis was predominantly associated 
with herpesviruses (51%, 95% CI: 41–64%), followed by M. tuberculosis (24%, 95% CI: 
15–35%) and T. pallidum (7%, 95% CI: 1–14%). The group of other infectious aetiology 
of uveitis included 8 (61%) patients with presumed bacterial aetiology, 1 (8%) patient 
of suspected cryptococcal uveitis and 4 (30%) patients with infectious uveitis of un-
known origin. Majority of patients (n=76; 74%) presented with uveitis only and 27 (26%) 
presented with accompanying keratitis, defined as keratouveitis. Infectious uveitis was 
more common among HIV-infected (83%) compared to HIV-uninfected individuals 
(51%) (OR=4.7, 95% CI: 1.9–11.8, P=0.001).
AH samples were obtained from 20 (53%) herpetic uveitis patients. VZV-induced 
uveitis was supported by PCR in 10 (50%) patients (median VZV PCR cycle threshold 
value of 24.5, range 17.5–34.5) of which 2 also had elevated intra-ocular VZV-specific 
IgG levels (data not shown) and by GWC alone in 2 patients. Ocular CMV infection was 
supported by PCR in only one patient. Clinical or laboratory evidence of HSV or EBV as 
cause of uveitis was not observed. Active M. tuberculosis infection was confirmed by 
chest X-ray examination in 8 of 15 (53%) TB-associated uveitis patients and by Xpert 
testing of sputum in 3 of 5 with concurrent productive cough. All TB-associated uveitis 
cases responded to standard TB treatment. T. pallidum serology was consistent with 
syphilitic-associated uveitis in 5 patients; all of whom were positive in three syphilitic 
tests.
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factors associated with uveitis aetiology
The following factors were associated with infectious uveitis (excluding keratouveitis 
as the pathogenesis thereof is substantially different): history of herpes zoster infection 
(P=0.05), history of TB (P=0.02), positive symptom screen for TB (P=0.05), HIV infection 
(P=0.017), severe visual impairment at presentation (P=0.003), elevated intra-ocular 
pressure (P=0.01) and poster location of uveitis (P<0.001) (table 1). By multivariate 
analysis, HIV infection (P=0.02) and severe visual impairment at presentation (P=0.002) 
were independently associated with infectious uveitis.
103 participants
Uveitis
n=76 (74%)
Infectious
n=47 (62%)
Herpetic
n=18 (38%)
Tuberculosis
n=18 (38%)
Syphilitic
n=5 (11%)
Other*
n=6 (13%)
Non-infectious
n=29 (38%)
Idiopathic
n=17 (59%)
Autoimmune**
n=12 (41%)
Keratouveitis
n=27 (26%)
Infectious
n=27 (100%)
Herpetic
n=20 (74%)
Bacterial
n=7 (26%)
66 (64%) HIV-infected
43 (57%) HIV-infected
23 (85%) HIV-infected 23 (85%) HIV-infected
11 (38%) HIV-infected
32 (68%) HIV-infected
11 (61%) HIV-infected
11 (61%) HIV-infected
4 (80%) HIV-infected
6 (100%) HIV-infected
6 (35%) HIV-infected
5 (42%) HIV-infected
18 (90%) HIV-infected
5 (71%) HIV-infected
figure 1. Aetiology of uveitis and HIV infection in study participants (n=103)
Uveitis and keratouveitis are shown separately as pathogenesis differs substantially.
*Including one case of suspected cryptococcal and one case of presumed bacterial uveitis.
**Including two patients with presumed sarcoidosis-associated uveitis, two patients with Fuchs’ hetero-
chromic uveitis and one patient with scleritis-associated uveitis.
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Among infectious uveitis patients, individuals with TB-associated uveitis were older 
(median age of 53 vs. 36 years, P=0.05) than patients with herpetic uveitis, but other 
factors were not associated with specific aetiology (data not shown).
table 1. Demographic and clinical characteristics stratified by infectious and non-infectious uveitis.
Infectious
uveitis
(n=47)
non-infec-
tious uveitis
(n=29)
total
(n=76)
crude odds
ratio
(95% cI)
P-value
Demographics and clinical history
Gender (male) 19 (40) 9 (31) 28 (37) 1.5 (0.6–4.0) 0.5
Age in years 42 (20–64) 46 (23–69) 43 (20–69) na 1.0
HIV-status
HIV-infected on ART 20 (43) 8 (28) 28 (37) 3.5 (1.3–9.2)a 0.02
HIV-infected ART naïve 12 (26) 3 (10) 15 (20)
HIV-uninfected 15 (32) 18 (62) 33 (43)
CD4 cell count in cells/mm³ 256 (9–813) 229 (62–831) 235 (9–831) na 0.5
Positive history of herpes zoster 14 (30) 3 (10) 17 (22) 3.7 (1.0–14.2) 0.05
Positive history of tuberculosis 14 (30) 2 (7) 16 (21) 5.7 (1.2–27.4) 0.02
Screening symptoms of tuberculosis 
present
23 (49) 7 (24) 30 (40) 3.0 (1.1–8.4) 0.05
Duration of ocular complaints in days 20 (1–296) 7 (2–63) 13 (1–296) na <0.0001
clinical characteristics
Visual acuity of the affected eye at enrolment
≥6/18 10 (21) 16 (55) 26 (34) 6.0 (1.8–19.9)b 0.003
<6/18 but ≥6/60 14 (30) 9 (31) 23 (30)
<6/60 but ≥3/60 6 (13) 0 (0) 6 (8)
<3/60 17 (36) 4 (14) 21 (28)
Intraocular pressure
Elevated intra ocular pressure 8 (19) 0 (0) 8 (11) na 0.01
Normal intra ocular pressure 34 (81) 29 (100) 63 (89)
Localization of uveitis
Anterior uveitis 24 (51) 22 (79) 46 (61) na <0.0001c
Intermediate uveitis 9 (19) 6 (21) 15 (20)
Posterior uveitis 13 (28) 0 (0) 13 (17)
Panuveitis 1 (2) 0 (0) 1 (1)
Data are shown as number (%) or median (range). CI, Confidence interval; P-value, Pearson Chi-square or 
Mann-Whitney-Wilcoxon U test; HIV, human immunodeficiency virus; ART, antiretroviral therapy; na, not 
applicable.
aCrude odds ratio and P-value were calculated for HIV-infected vs. HIV-uninfected.
bCrude odds ratio and P-value were calculated for patients with visual acuity of < 6/60 (severe visual impair-
ment or blindness) vs. patients with visual acuity of ≥ 6/60 (no to moderate visual impairment).
cP-value was calculated for patients in which the posterior segment was affected vs. patients in which the 
posterior segment was not affected.
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DIScuSSIOn
This study reports on the aetiology of uveitis in a unique sample of uveitis patients 
living in rural South Africa. We report that uveitis of infectious aetiology is more com-
mon among HIV-infected individuals, in particular uveitis caused by herpesviruses, M. 
tuberculosis and T. pallidum. Furthermore, it is not unlikely that some of the patients 
classified as idiopathic uveitis in this study also had an infectious aetiology of uveitis but 
could not be detected by the currently available laboratory resources.
The data implicate that infectious uveitis is considerably more common in rural South 
Africa than reported from other regions of the world, including from other resource-
poor settings such as rural India [1, 8]. Given the significant association observed here 
between HIV infection and infectious uveitis, the difference is most likely due to the high 
HIV prevalence in the Mopani region [1, 9]. Among HIV-infected individuals, ART did not 
significantly decrease the risk of infectious uveitis, but this might have been due to the 
relatively low median CD4 count in HIV-infected uveitis patients on ART. In addition to 
HIV, other factors such as geographic differences in prevalence of pathogens, infection 
pressure and socioeconomic factors may also have contributed to higher frequency of 
infectious uveitis observed [1].
Few studies, all from more than 10 years ago, have reported on the distribution of 
uveitogenic pathogens in sub-Saharan Africa, mainly diagnosed on clinical rather than 
on laboratory data [10-13]. Whereas Toxoplasma gondii was reported earlier as major 
uveitis-inducing pathogen, we report on the predominant role of herpesviruses. Nota-
bly, none of our participants presented with clinical characteristics suggestive for ocular 
toxoplasmosis. The high prevalence of herpetic uveitis, mainly VZV, is most likely due 
to the high herpesvirus infection rate in the Mopani district [13-14]. Congruent with an 
earlier study from Congo, demonstrating that 38 of 89 uveitis cases among HIV-infected 
individuals were VZV-induced, VZV was the most common viral cause of infectious uveitis 
in our study [13]. Despite a CMV seroprevalence of 100% among HIV-infected ART-naïve 
individuals in the Mopani district, we observed only a single case of CMV retinitis. This 
confirms previous reports describing CMV as rare cause of uveitis in sub-Saharan Africa, 
which contrasts studies on uveitis patients from developed countries describing CMV 
as the most important uveitogenic pathogen among HIV-infected individuals [14-16]. 
Indeed, a study from Tanzania demonstrated that only 2 of 150 HIV-infected uveitis pa-
tients with CD4 counts ≤100 cells/mm³ had CMV retinitis, suggesting that factors of virus 
or host origin contribute to the geographic differences in CMV uveitis prevalence [15].
In addition to herpesviruses, M. tuberculosis was a common cause of uveitis in our 
study confirming previous reports from other TB endemic settings that show an increas-
ing aetiological role of M. tuberculosis in uveitis [17]. Indeed, TB uveitis was also the most 
common cause of infectious uveitis in India [18]. We were able to confirm TB disease by 
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routine diagnostics in about half of our TB uveitis patients, whereas ocular character-
istics observed in eye examination including fundoscopy (e.g. chronic granulomatous 
uveitis with mutton-fat keratic precipitates or chorioretinal granuloma) were the only 
evidence of TB in the remaining group. Recognition of M. tuberculosis infection as cause 
of uveitis is of great importance as there is paucity of data and limited awareness of 
ocular TB involvement. The national TB guidelines of South Africa, one of the countries 
with highest TB burden globally, does not include any information on diagnosis and 
management of ocular TB [19].
The contribution of T. pallidum infection as cause of infectious uveitis in sub-Saharan 
Africa is largely unknown. The relative high number of syphilitic uveitis cases reported 
here is in line with recent observations from non-African countries describing an in-
creasing incidence of ocular syphilis [20-21]. Recognition is important as diagnosis of 
syphilitic uveitis is difficult as clinical characteristics of syphilitic uveitis are diverse and 
can simulate any form of uveitis. As such, serological evaluation for syphilis is indicated 
in uveitis patients from high T. pallidum incidence populations.
A potential limitation of our study is that it was conducted at hospital and not at 
primary healthcare level. This may have resulted in selection bias due to ineffective 
referral of uveitis cases from primary healthcare facilities to hospitals. It is also likely that 
mild uveitis cases were missed at primary healthcare level and therefore not presented 
to the hospital, including cases of immune recovery uveitis as this condition is usually 
asymptomatic or self-limiting if symptomatic [22]. Another limitation of our study is that 
diagnostic aspiration of AH was not obtained from all study participants. This may have 
resulted in underdiagnoses of human herpesvirus induced uveitis.
In conclusion, uveitis confers a complex disease entity with predominantly infectious 
aetiology in areas where HIV and TB are endemic. In these settings, a high index of suspi-
cion for an infectious origin of uveitis is warranted as guided by clinical and ophthalmo-
logical findings and preferably supported by laboratory evaluations. Additionally, HIV 
counselling and testing should be performed in all patients with uveitis considering the 
strong association between these two conditions.
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AbStrAct
Mycobacterium tuberculosis infection is an important cause of sight-threatening chorio-
retinitis in HIV-infected individuals living in M. tuberculosis endemic areas. We present a 
case of tuberculous chorioretinitis in a HIV-infected man after recent initiation of antiret-
roviral therapy in rural South Africa, who had nearly complete resolution of clinical signs 
and symptoms after standard tuberculosis treatment. His presentation was most likely 
associated with immune reconstitution inflammatory syndrome.
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Tuberculous chorioretinitis
IntrODuctIOn
Ocular tuberculosis (TB), including tuberculous chorioretinitis, is an important and 
sight-threatening condition in human immunodeficiency virus (HIV)-infected individu-
als [1-3]. TB associated with immune reconstitution inflammatory syndrome (IRIS) after 
antiretroviral therapy (ART) initiation is a specific condition that is well-documented for 
pulmonary disease, but not for ocular presentation.
cASE
A 57-year-old HIV-infected man presented at the eye clinic of a hospital in rural South 
Africa. The patient complained of an acute loss of vision, ocular pain and photophobia of 
the left eye for two weeks without any other systemic complaints. Three months earlier 
he had initiated ART at low CD4 count (135 cells/µL). He was successfully treated for 
pulmonary tuberculosis more than a decade ago.
On examination, visual acuity in the left eye was only ‘hand motion’ and vision in 
the right eye was normal. Slit-lamp examination of the left eye showed mild anterior-
chamber inflammation without posterior synechiae. At fundoscopic examination a 
chorioretinal granuloma was observed in the superotemporal quadrant of the retina 
accompanied by papilledema, retinal vasculitis and minimal vitritis (binocular indirect 
ophthalmoscope score of 1) (figure 1A). There were no other signs of active TB and 
chest X-ray was consistent with past TB. Unfortunately, valuable additional investiga-
tions like optical coherence tomography and interferon gamma release assays are not 
available in rural South Africa.
A B
figure 1. (A) Fundus photograph of the left eye at presentation showing a chorioretinal granuloma, pap-
illedema, retinal vasculitis and minimal vitritis. (b) Fundus photograph of the left eye after two months, on 
standard Mycobacterium tuberculosis treatment and topical corticosteroid eye drops, showing an almost 
completely resolved granuloma, no papilledema and hard exudates within the macula.
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Based on the typical retinal abnormalities a diagnosis of TB chorioretinitis, most likely 
associated with immune reconstitution inflammatory syndrome (IRIS), was established. 
TB treatment and topical corticosteroid eye drops were given. Two months later the 
ocular granuloma had almost completely resolved, and the papilledema and retinal 
vasculitis had normalised (figure 1b). Post-infectious hard exudates within the macula 
remained. Visual acuity had improved dramatically to nearly normal vision (6/7,5).
cOmmEnt
Ocular TB is an important infectious ocular disease among HIV-infected individuals and 
may involve the anterior and posterior segment of the eye [1-3]. Although introduction 
of ART has led to a decrease in ocular infections, ocular IRIS is a serious complication 
of HIV-infected individuals who are initiated on ART, particular those with a low CD4 
cell count [1, 4]. Unlike pulmonary infection, tuberculous chorioretinitis without other 
signs has rarely been described as ocular manifestation of IRIS [5]. TB-IRIS may result 
from paradoxical worsening of previously treated infection or from unmasking of a 
subclinical or unrecognised infection after the initiation of ART [1, 4]. Treatment options 
of ocular TB, including TB chorioretinitis, are identical to other extra-pulmonary types of 
TB and may be supplemented with topical steroids [3, 6]. Visual outcome is usually good 
if recognised promptly and treated adequately [2-3, 6].
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Ocular diseases are a significant health problem worldwide that impact greatly on 
quality of life of individuals affected as well as their families and communities [1-4]. 
The prevalence of visual impairment is unequivocal distributed worldwide and the 
burden of visual disability is disproportionally high in low-resource countries with up 
to ninety percent of visually impaired individuals living in these settings [5-7]. Although 
there is a paucity of local epidemiological and clinical data on visual impairment and 
ocular disease from sub-Saharan African countries, the coinciding high human immu-
nodeficiency virus (HIV) prevalence most likely contributes not only to the burden of 
visual impairment, but also increases the role of serious and sight-threatening ocular 
infections because HIV-infected individuals are at increased risk of developing ocular 
(infectious) disease [8-13]. For South Africa, 6.8 million individuals are living with HIV, all 
of whom are at risk of suffering from HIV-related sight-threatening ocular disease due 
to immunodeficiency [14-16]. However, data on the local epidemiology, aetiology and 
burden of ocular disease from settings with high HIV prevalence like South Africa are 
practically unavailable, but highly warranted to improve management of ocular disease 
and to guide ophthalmological prevention programs [5-6].
The main aim of the studies presented in this thesis was to provide novel insight 
into ocular diseases in a high HIV prevalence and low-resource setting in rural South 
Africa. We determined the seroprevalence of human herpesviruses (HHVs), known for 
their major role in HIV-related ocular disease, in HIV-infected antiretroviral therapy 
(ART)-naïve individuals (chapter 2). Furthermore, we focused on two major causes of 
significant ocular morbidity, infectious keratitis and uveitis, by determining the cause 
and clinical manifestations and present a unique case of tuberculous uveitis in a HIV-
infected man shortly after initiation of antiretroviral therapy (ART) (chapter 3, chapter 
5 and chapter 6). During our studies we identified a public health challenge among 
HIV-infected individuals with herpes zoster ophthalmicus (HZO), which often resulted in 
visual impairment. We studied the spectrum of ocular complications of varicella-zoster 
virus (VZV) infection to provide clinical data to improve management and outcome of 
individuals with HZO (chapter 4). Finally, the introduction of ART in South Africa has re-
sulted in prolonged survival of HIV-infected individuals and to a shift in the spectrum of 
ocular disease [17-19]. It is thought that HIV-infected individuals on ART are at increased 
risk of age-related morbidity and mortality such as cardiovascular disease and diabetes 
compared with HIV-uninfected individuals [18, 20-21]. However, the long-term effects of 
ART and chronic HIV infection on the prevalence of ocular disease are largely unknown. 
We described the distribution of ocular disease and manifestations among HIV-infected 
individuals with and without ART in rural South Africa (chapter 7).
All studies presented in this thesis were conducted in the rural Mopani District of the 
Limpopo Province (South Africa). Mopani District is one of South Africa’s national prior-
ity districts based on poor quality of healthcare and high poverty rates, illiteracy and 
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unemployment and it has one the highest HIV prevalence rates (24.6% among pregnant 
women in 2013) in South Africa [22].
HumAn HErPESVIruSES In rurAl SOutH AfrIcA
HHVs are a major cause of ocular morbidity as they frequently cause sight-threatening 
ocular conditions such as keratitis and uveitis. Among the eight known HHVs, cytomega-
lovirus (CMV) and particularly the human alphaherpesviruses (αHHVs) herpes simplex 
virus type 1 (HSV-1) and VZV are the main keratogenic and uveitogenic HHVs [23]. 
Seroprevalence of HHVs among the human population is high. However, data from sub-
Saharan African countries are limited and seroprevalence rates are known to vary from 
region to region [24]. The hallmark of HHVs is their ability to establish lifelong latency and 
reactivate intermittingly, which is commonly asymptomatic [25]. HIV-infected individu-
als are at increased risk for HHV-related disease compared to HIV-uninfected individuals 
due to an increased risk of symptomatic reactivation as a result of HIV-induced immu-
nodeficiency [26-28]. Available data on HHV-associated ocular disease in HIV-infected 
individuals are mainly from Western countries such as the United States of America 
(USA) where CMV retinitis affected up to 40% of HIV-infected individuals in the pre-ART 
era leading to severe visual impairment [15-16, 29]. CMV retinitis was predominantly 
observed in individuals with severe immunodeficiency, typically when CD4 cell counts 
were below 50 cells/mm³ [15-16]. As ART became widely available, the incidence of CMV 
retinitis in Western countries decreased significantly as shown by a study from France 
describing a decreased incidence of newly diagnosed CMV retinitis from 6% before the 
wide spread use of ART to 1% in the ART era [18, 30]. However, even after the initiation 
of ART, though to a far lesser extent than in the pre-ART era, HIV-infected individuals are 
at increased risk of developing HHV-related ocular disease as a result of ART-induced 
recovery of the host’s adaptive immunity potentially leading to debilitating Immune re-
constitution inflammatory syndrome (IRIS), also known as immune restoration disease, 
that may be accompanied with intra-ocular HHV-specific cellular immune responses like 
immune recovery uveitis due to CMV reactivation [31-32].
Sub-Saharan African countries are hit hardest by the HIV epidemic, but data on the 
seroprevalence of HHVs among HIV-infected individuals are limited [33]. We addressed 
this important issue by determining the seroprevalence of HSV-1, HSV-2, VZV, CMV and 
Epstein-Barr virus (EBV) in a cohort of HIV-infected ART-naïve individuals in rural South 
Africa. We described that HHV seroprevalence in this population is very high: HSV-1 
(98%), HSV-2 (87%), VZV (89%), and 100% for EBV and CMV (chapter 2) [34]. This find-
ing is of paramount importance as limited attention is given to these infections in the 
clinical management of HIV-infected individuals in South Africa, despite their increased 
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risk of developing HHV-related ocular disease. Our results warrant increased awareness 
among healthcare providers in these settings for early clinical signs of HHV-related 
(ocular) disease to initiate prompt antiviral treatment to prevent (ocular) morbidity. Also, 
increased awareness among and education of HIV-infected individuals on early signs 
and symptoms of HHV infections is of great importance to ensure early presentation 
to healthcare facilities for diagnosis and management as many individuals in resource-
limited settings present to healthcare facilities with an extended patient delay [35-37]. 
For example, a substantial delay (medial of 5 days) in healthcare seeking for signs and 
symptoms suspected for HZO due to VZV was observed among individuals in South 
Africa as few sought care within the optimal time frame (≤72 h after onset of rash) 
for antiviral treatment [38]. Similarly, a significant delay for genital ulcer disease was 
observed among men in South Africa as few sought care within 24 hours, the optimal 
time frame for acyclovir initiation [35]. The high HHV seroprevalence observed in our 
study also warrants the need for enhanced HHV-related disease control as they clinically 
interact with HIV and particular HHVs may even facilitate HIV-transmission [39-41]. For 
example, HSV-2 infection increases both susceptibility to HIV and transmissibility of HIV 
infection [41]. As such, the high seroprevalence of HSV-2 in our population most likely 
contributes to the transmission of HIV which poses a serious challenge and warrants 
implementation of intervention strategies to reduce HSV-2 related HIV transmission. 
One strategy could be “treatment as prevention” for HIV/HSV-2 co-infected individuals 
in which ART is initiated regardless to the CD4 cell count to reduce HIV transmission to 
their sexual partners [42].
We identified several factors associated with HHV serostatus such as low socioeco-
nomic status (for HSV-1), Shangaan ethnicity (for HSV-2) and low educational status 
(for VZV) (chapter 2) [34]. However, these results should be interpreted with caution. 
Overall HHV seroprevalence was very high resulting in a relative small group of serone-
gative individuals. No association was observed between the individual’s seropositive 
HHV status and a history of corresponding HHV-specific clinical symptoms. Finally, we 
observed a negative association between EBV and CMV IgG titres with CD4 cell count. 
A possible reason for this negative association is that decreasing CD4 cell count due to 
HIV replication is associated with activation of CMV- and EBV-specific CD4 cells as part of 
chronic immune activation, which may subsequently stimulate humoral responses and 
produce higher IgG titres. This is an important finding and emphasises the importance 
of early ART initiation to prevent advanced HIV-related immunodeficiency and subse-
quently limit HHV related disease.
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InfEctIOuS KErAtItIS
The aetiology of infectious keratitis is diverse and includes infections with viruses, bac-
teria and fungi [43-44]. Although HIV-infected individuals have an increased risk of viral 
keratitis, especially VZV related keratitis, clinical practice in South Africa predominantly 
emphasizes on a bacterial aetiology of keratitis [45]. As a result, pre-emptive antibiotic 
treatment are commonly provided to patients presenting with clinical signs of infec-
tious keratitis. Because the latter dogma is largely based on clinical data, we performed 
a study aimed to compare the clinical and corneal microbial profile of infectious keratitis 
patients (n=46) in a high HIV prevalence setting to set priority in the development of 
clinical guidelines for infectious keratitis in rural South Africa (chapter 3). This cross-
sectional study showed that αHHVs, especially VZV and in part complicated by bacte-
rial infections, play a major role in infectious keratitis and lead to pronounced visual 
morbidity [46]. The important role for viral aetiology of infectious keratitis has not been 
observed in previous studies from sub-Saharan African countries and might be related 
to the high HIV prevalence in our setting as we observed a statistical trend between 
HIV infection and viral keratitis (chapter 3) [46-48]. Unfortunately, previous studies on 
infectious keratitis from sub-Saharan Africa do not report on the patient’s HIV status [47-
48]. We included patients at the outpatient department of hospitals and not at primary 
healthcare (PHC) facilities. This might have resulted in some degree of bias towards viral 
keratitis as potential bacterial cases are more likely treated successfully at PHC level as 
pre-emptive treatment of infectious keratitis in South Africa consists of topical antibiot-
ics (e.g. chloramphenicol) only. We identified VZV as the most prevalent viral cause of 
infectious keratitis in our study population, which is in contrast to previous studies from 
other sub-Saharan African countries and high-resource Western countries where HSV-1 
was identified as the most prevalent keratogenic pathogen [28, 47-48]. One reason for 
the important role of VZV in our study might be the high HIV prevalence. The increased 
risk of VZV keratitis for HIV-infected individuals is well studied, but data on the associa-
tion between HIV infection and HSV-1 keratitis are limited [45, 49-52]. Although available 
data shows that the recurrence rate of HSV-1 keratitis is increased among HIV-infected 
individuals compared to uninfected individuals, the incidence of HSV-1 keratitis seems 
to be similar [52]. Another reason for the important role of VZV in our study might be 
due to some degree of selection bias. VZV keratitis is usually associated with cutaneous 
HZO, which makes it relatively easy to identify for non-ophthalmic trained healthcare 
providers that work at PHC facilities. As such, referral of these patients to the ophthal-
mology outpatient department of hospitals is likely. In contrast, HSV-1 keratitis is more 
difficult to diagnose for non-ophthalmic trained healthcare providers due to a lack of 
concomitant clinical characteristics. These cases might not be recognized as keratitis 
and subsequently not referred to hospitals as frequent as VZV keratitis cases. We noticed 
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that there is even among ophthalmic nurses working at the ophthalmology outpatient 
department of hospitals an extensive lack of knowledge about viral HSV-1 keratitis 
[Schaftenaar E; unpublished data]. For example, when we retrospectively reviewed 
patient files of patients diagnosed with keratitis, topical antivirals were prescribed ex-
clusively to patients presenting with cutaneous HZO [Schaftenaar E; unpublished data].
In our study, we demonstrated that polymerase chain reaction (PCR) analysis of cor-
neal swabs is a valuable diagnostic platform to detect viral DNA and supports clinical 
observations of herpetic keratitis in cases with epithelial inflammation (chapter 3) [46]. 
We consider PCR analysis of corneal swabs of significant diagnostic value and propose 
that this methodology should be introduced in the routine management of patients in 
rural South Africa presenting with epithelial keratitis of potential viral aetiology. How-
ever, in cases with subepithelial inflammation, PCR results of corneal swabs were often 
negative, even though the clinical presentation and response to antiviral treatment was 
suggestive for herpetic keratitis (chapter 3) [46]. Consequently, determination of the 
pathogen involved using PCR analysis of corneal swabs in keratitis patients remains 
challenging. As ophthalmological expertise in these settings is very limited, correct 
diagnosis solely based on clinical characteristics is highly unlikely. Corneal scraping 
might be an alternative to corneal swabbing in cases with subepithelial inflammation 
and will improve aetiological diagnosis [53]. However, corneal scraping bears higher 
risks (e.g. bacterial superinfection) as the procedure is more invasive than corneal swab-
bing. Future studies to elucidate the diagnostic value and potential complications of 
corneal scraping in high HIV prevalent settings with limited ophthalmological expertise 
is warranted. In our study, bacteria were detected in almost half of the viral keratitis 
cases, but unlike other studies bacterial superinfection of the cornea was not associ-
ated with poorer visual outcome (chapter 3) [46, 54]. However, we do advocate to 
perform microbial examination of corneal swabs because bacterial superinfections are 
common and might lead to poorer outcomes if left untreated. Fortunately, microbial 
analysis, including Gram-stain microscopy and culture, of corneal swabs for bacteria 
and fungi is available in most hospitals in South Africa. However, to be cost-effective in 
resource-limited settings, we consider that laboratory analyses of corneal swabs (PCR 
analysis and microbial examination) should be performed at District level hospitals only. 
A fungus was detected in only one keratitis case, which is in contrast to a study from 
Tanzania that reports fungi as a common causative pathogen among culture positive 
cases of microbial keratitis [55]. The low number of fungal keratitis cases observed in our 
study may be due to the exclusion of traumatic keratitis as most fungal keratitis cases 
are trauma related [56]. Furthermore, this may also be correlated to geographical differ-
ences as fungal keratitis is more likely to occur toward tropical latitudes [44, 56]. Anterior 
uveitis was an important complication of infectious keratitis and was significantly more 
common among HIV-infected than HIV-uninfected individuals (chapter 3) [46]. Thus, 
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concomitant anterior uveitis in patients presenting with infectious keratitis may point 
at undiagnosed HIV infection, which warrants subsequent HIV counselling and testing.
Early diagnosis of infectious keratitis and consequently initiation of targeted antimicro-
bial treatment is of paramount importance to prevent ocular morbidity because poorer 
visual outcome was associated with increased time between onset of symptoms and 
first presentation at the ophthalmology department of hospitals (chapter 3) [46]. This 
remains challenging, especially in resource- and skills-constrained settings (chapter 3) 
[44, 46, 56]. Current management of infectious keratitis in rural South Africa emphasizes 
(presumptive) antibacterial treatment rather than identifying the triggering pathogen 
[57]. In addition, topical antivirals (e.g. acyclovir) are unavailable at PHC facilities and 
were hardly used in the ophthalmology outpatient department of hospitals before 
the study [Schaftenaar E; unpublished data]. Our results suggest that current manage-
ment leads to significant under-treatment and possible preventable blindness as viral 
aetiology is very common (chapter 3) [46]. Therefore, we advocate that presumptive 
treatment of patients presenting with infectious keratitis to PHC facilities should include 
both topical antibiotic and antiviral treatment to prevent ocular morbidity. To improve 
diagnosis, microbial examination and PCR analysis, in cases with epithelial inflammation, 
of corneal swabs should be performed in patients presenting with infectious keratitis. 
In addition, training of PHC nurses on basic ophthalmology skills including eye exami-
nation is warranted to ensure early identification of keratitis, initiation of appropriate 
treatment and reinforce prompt referral to ophthalmology outpatient departments of 
hospitals to prevent further delay.
HErPES ZOStEr OPHtHAlmIcuS
HZO is the clinical manifestation of reactivation of latent VZV infection in the ophthalmic 
branch of the trigeminal ganglion [58]. Ocular involvement occurs in more than half of 
patients with untreated cutaneous HZO, leading to ocular morbidity [49-50, 59-60]. Rela-
tive mild acute ocular complications of HZO may progress to chronic disease, which are 
associated with severe visual impairment if left untreated [49-50]. HIV-infected individu-
als are at increased risk of developing HZO, but limited data are available on the ocular 
manifestations of HZO in high HIV prevalence settings in sub-Saharan Africa [45, 51, 61].
In our study on HZO, ocular complications were classified as “early” or “late” based on 
stage of disease progression and (potential) restoration of normal vision, which resulted 
in a unique clinical classification system of ocular complications of HZO (chapter 4) [62]. 
Our study revealed that the spectrum of ocular complications of HZO among patients 
presenting to the ophthalmology outpatient department in a high HIV prevalence 
setting is diverse and that late-stage ocular complications are common and associated 
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with blindness (chapter 4) [62]. Increased time interval between onset of symptoms 
and first presentation to the facility was associated with late-stage ocular complications 
(chapter 4) [62]. This is most likely due to delayed initiation of antiviral treatment as 
early initiation thereof (≤72 hours after onset of rash) reduces the risk of progression of 
early- to late-stage ocular complications [50, 63]. Specific reasons for this delay remain 
unclear and requires further investigation. Most likely, both patient- and healthcare 
system-associated factors like referral delay have played a role. Our results emphasize 
the importance of early recognition of cutaneous HZO and ocular involvement, prompt 
initiation of appropriate antiviral treatment even at PHC level with swift referral to hos-
pitals with ophthalmology departments to reduce sight-threatening ocular complica-
tions. Appropriate antiviral treatment should be available at PHC level, even in rural and 
resource-limited settings (chapter 4) [62]. To achieve early recognition of cutaneous 
HZO and ocular involvement, training of healthcare providers at both PHC facilities 
and hospitals is of paramount importance and should include basic ophthalmological 
training and training around prescription and instalment of topical and oral antiviral 
treatment. Moreover, these efforts should result in the development of clinical guide-
lines and standardized training programs to prevent ocular morbidity among patients 
with HZO. Also to reduce delay in patients seeking medical care, community campaigns 
should be initiated to increase awareness among HIV-infected individuals and prevent 
visual impairment.
In our study, HIV infection was common among patients presenting with HZO and 
intraocular complications were more common among HIV-infected than HIV naïve in-
dividuals which is in line with previous studies [45, 49-51]. Even though several studies 
have advocated that HZO can be a HIV presenting clinical disease, 4/39 (10%) of HIV-
infected individuals presenting with HZO were tested reactive for HIV for the first time at 
the ophthalmology outpatient department [45, 49, 64-65]. We therefore advocate that 
HIV testing and counselling should be standard practice in patients presenting with HZO 
in high HIV prevalence settings and encourage discussion among healthcare providers 
about the introduction of HIV testing and counselling in all patients presenting with 
HZO (chapter 4) [62].
uVEItIS
Uveitis is a sight-threatening eye condition that is a common cause of visual impairment 
in low-resource settings [66]. The aetiology of uveitis is diverse and includes infectious 
and non-infectious disorders [66-67]. Data from sub-Saharan African countries are 
limited, but suggest that infectious diseases play an important role in uveitis [66]. The 
high HIV prevalence in these countries most likely contributes to the role of infectious 
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diseases in uveitis as HIV-infected individuals are at increased risk of developing infec-
tious uveitis [66, 68-69].
In this thesis we conducted a cross-sectional study among patients presenting with 
uveitis (n=103) and found that infectious uveitis is common in our population, especially 
among HIV-infected individuals. The most prevalent uveitogenic pathogens identified 
were HHVs (51%), Mycobacterium tuberculosis (24%) and Treponema pallidum (7%) 
(chapter 5) [70]. The data implicate that infectious uveitis is considerably more common 
in the setting studied, than reported in other regions of the world [66]. For example, 
infectious uveitis only accounts for about 10-20% of uveitis cases in high-resource coun-
tries like the USA, Portugal, United Kingdom and the Netherlands [66]. Herpetic uveitis, 
mainly VZV, was the major cause of infectious uveitis in our South African patient cohort 
and is most likely due to the high HIV prevalence and high HHV seroprevalence in our 
setting [34, 71]. The predominant role for VZV is in line with a study from Congo that 
reported VZV infection as the most common associated condition among HIV-infected 
uveitis patients, but in contrast to studies from high-resource settings like the USA that 
report a predominant role for CMV, especially in the pre-ART era [71-74]. Despite of a 
CMV seroprevalence of 100% among HIV-infected ART-naïve individuals in our setting, 
we observed only a single case of CMV uveitis [34]. A possible reason for the observed 
low prevalence of CMV uveitis and high prevalence of VZV uveitis in our study is the rela-
tive high CD4 cell count among HIV-infected individuals at inclusion (chapter 5) [70]. 
CMV uveitis typically occurs in patients with CD4 cells ≤50 cells/mm³, whereas herpes 
zoster ophthalmicus and associated VZV uveitis already occurs in patients with CD4 
cells ≤500 cells/mm³ [13, 72, 75]. In our study, only 3 (5%) HIV-infected uveitis patients 
presented with CD4 cells ≤50 cell/mm³, making them at risk of CMV uveitis (chapter 5) 
[70]. In contrast, 54 (82%) HIV-infected uveitis patients presented with CD4 cell counts 
between 50 and 500 cells/mm³. However, other factors like virus or host origin factors 
might contribute to the geographic differences in CMV uveitis prevalence as a study 
from Tanzania reported low prevalence of CMV uveitis (1.3%) even among HIV-infected 
uveitis patients with CD4 cells ≤100 cells/mm³ [76].
In addition to HHVs, M. tuberculosis was a common cause of uveitis in our study 
confirming previous reports from other low-resource settings like India that showed an 
increasing uveitogenic role of M. tuberculosis (chapter 5) [70, 77-78]. However, avail-
able data on ocular tuberculosis (TB) is predominantly from non-sub-Saharan African 
counties where the TB epidemic differs substantially from the TB epidemic of South 
Africa [79]. In South Africa, the TB epidemic is fuelled by the high HIV prevalence and 
HIV-infected individuals are at increased risk of developing ocular TB [79-81]. Our results 
are of great importance and warrant recognition of M. tuberculosis infection as cause 
of uveitis in South Africa. Currently, there is a paucity of data and limited awareness 
among policy makers and healthcare providers, even among those working at the 
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TB wards, of ocular involvement of TB in South Africa. The South African national TB 
guideline for example does not include any information on diagnosis and management 
of ocular TB [82]. With the significant role of TB observed in our study, renewal of clinical 
guidelines and education of healthcare providers on ocular involvement of TB are of 
great importance (chapter 5) [70]. This thesis also presents an interesting case history of 
TB chorioretinitis in a HIV-infected man early after ART treatment, which was most likely 
associated with the immune reconstitution inflammatory syndrome (chapter 6) [83]. 
This case highlights the importance of screening for (ocular) TB and basic ophthalmo-
logical examination (e.g. visual acuity testing) after ART initiation as part of the routine 
follow-up visits after ART initiation of HIV-infected individuals. It also highlights that 
ocular immune reconstitution inflammatory syndrome can be of other origin than CMV 
retinitis, which is predominantly advocated in available literature [31-32, 84].
Whereas T. pallidum is a known uveitogenic pathogen, its contribution as cause of in-
fectious uveitis in sub-Saharan Africa is largely unknown and diagnosis remains a major 
clinical challenge [85]. Here, we report on a relative high number of syphilitic uveitis 
cases, which is in line with recent observations from non-African countries suggest an 
increasing incidence of ocular syphilis (chapter 5) [70, 86-88]. In our study, all clinical 
findings observed during slit-lamp and funduscopic examination were reviewed by a 
team of uveitis specialists using the photographs of anterior and posterior segment of 
the eye and diagnosis of ocular syphilis was based on clinical characteristics consistent 
with ocular syphilis in individuals with laboratory confirmed syphilis [88-90]. Although 
few studies have reported possible contribution of PCR testing or Goldmann-Witmer 
coefficient determination on intraocular fluid in the diagnosis of ocular syphilis, the 
usefulness of these assays remains to be determined [91-92]. Recognition of the high 
number of syphilitic uveitis cases is important as diagnosis is difficult because clinical 
characteristics of syphilitic uveitis are diverse and mimics other uveitis entities [85].
Early diagnosis and prompt initiation of targeted antimicrobial treatment is of 
paramount importance for good visual outcome of infectious uveitis [93-95]. Accurate 
diagnosis of uveitis cases, especially in resource-limited settings and in HIV-infected 
individuals, is challenging for multiple reasons [68, 96]. First, uveitis is generally clini-
cally underdiagnosed due to lack of ophthalmological expertise [68]. Significant visual 
impairment was reported due to unrecognised uveitis among Ugandan HIV-infected 
individuals. Visual impairment in these cases could possibly have been prevented if 
recognised at early onset of disease [96]. Second, if uveitis is diagnosed clinically, the 
presumption of aetiology may be incorrect as this is based on the patient’s history, clini-
cal and ophthalmological characteristics. Clinical characteristics in uveitis have poor pre-
dictive value for its aetiology. They do not distinguish well between infectious and non-
infectious origin and, in case of infectious uveitis, are poorly predictive for the causative 
pathogen because different pathogens may present with similar clinical characteristics 
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[93-94]. For example, the initial clinical diagnosis was adjusted and treatment altered 
based on diagnostic testing in almost a quarter of patients presenting with uveitis in 
studies from the Netherlands and South Africa [93-94]. One exception might be uveitis 
caused by M. tuberculosis: the patient’s history (e.g. recent history of pulmonary TB) or 
specific retinal findings (e.g. granuloma) are strongly indicative for ocular TB. However 
tuberculosis cannot always be ruled-out solely on clinical symptoms [97]. For example, 
in our uveitis study, we were able to confirm TB by routine diagnostics in about half of 
our TB uveitis patients (chapter 5) [70]. In the other half, ocular characteristics sugges-
tive of ocular TB like chronic granulomatous uveitis with mutton-fat keratic precipitates 
or a chorioretinal granuloma were the only evidence of TB. Isolation of M. tuberculosis 
from the ocular tissues is the cornerstone for diagnosis, but rarely achievable as ocular 
specimens are usually too small and culture takes long [98]. Detection of mycobacterial 
DNA through PCR strongly supports diagnosis of ocular TB, but is currently not widely 
used and its additional diagnostic value remains largely unclear [98-99]. Third, empirical 
treatment of infectious uveitis is difficult because of the wide range of potential uveito-
genic pathogens that require targeted treatment. Finally, HIV infection and its associ-
ated immunosuppression affect the differential diagnosis as HIV-infected individuals 
have an increased risk for specific HIV-associated ocular opportunistic infections [68]. In 
addition, disease manifestation of infectious uveitis in HIV-infected individuals is usually 
atypical (e.g. lower degree of inflammation; even in advanced uveitis) compared to per-
sons without HIV infection. This challenges the clinical identification of the triggering 
pathogen in this patient group [68].
Presumed clinical diagnosis of infectious uveitis is increasingly supported in Western 
countries by analysis of ocular fluid, especially aqueous humour (AH) [100]. Ocular fluid 
is obtained through diagnostic anterior chamber paracentesis and AH aspiration. This 
is a well-documented procedure that is routinely performed in other aspects of oph-
thalmologic care, e.g. for management of acute elevation of intraocular pressure and 
for diagnosis of suspected intraocular infections, metastasis and lymphoma [94-95]. The 
two key diagnostic tests include pathogen-specific serology of paired ocular fluid and 
serum samples and PCR on the ocular fluid sample. In serology, intra-ocular pathogen-
specific IgG is measured and compared to serum IgG levels (Goldmann-Witmer coeffi-
cient) to differentiate between intra-ocular production of antibody and passive leakage 
from the blood as proxy for infection, whereas PCR identifies pathogen-specific nucleic 
acids [101]. In infectious uveitis, pathogen-specific nucleic acids and IgG production are 
commonly detectable at different times after onset of disease. During the early phase, 
nucleic acids are detectable (within days after onset disease) followed by detection of 
intra-ocular IgG levels. Whereas pathogen nucleic acids commonly become undetect-
able two weeks after onset of disease, specific antibodies remain detectable for multiple 
weeks in AH [101]. Thus, both assays are complimentary and contribute considerably 
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to the differential diagnosis of infectious uveitis [93-95, 101-102]. Identification of 
the triggering pathogen was established by serology and PCR in 60% of HIV-infected 
individuals presenting with undefined posterior uveitis in a study from Italy, whereas 
PCR provided a final diagnosis in 39% of cases where the initial diagnosis of causative 
pathogen was uncertain in a study from South Africa [93, 102]. Furthermore, treatment 
was altered on basis of PCR results in 20% of patients with posterior uveitis of suspected 
infectious origin in a study from USA [95]. In our study, AH samples were only obtained 
from participants with severe visual impairment as this procedure is not part of standard 
clinical practice in South Africa (chapter 5) [70]. In case of herpetic uveitis patients, AH 
was obtained from 20 (53%) patients and specific diagnosis based on analysis of aque-
ous humour was established in the majority (65%) of patients (chapter 5) [70]. Clinical 
or laboratory evidence of HSV-1, HSV-2 or EBV as cause of uveitis was not observed 
(chapter 5) [70].
Anterior chamber paracentesis is a safe procedure that can be performed in a consul-
tation room at the slit-lamp [103-104]. Three studies reported on safety of this proce-
dure to diagnose uveitis [103-105]. There were only a few, non-serious, complications 
reported: traumatic hyphaemia (5 cases per 1,000 procedures) and injection of air into 
the anterior chamber (4 cases per 1,000 procedures) as the most important. Hyphaemia 
refers to bleeding in the anterior chamber that may cause blurred vision, but this will 
usually resolve spontaneously or is easily treatable with topical drops (e.g. topical ste-
roids). Similarly, injection of air into the anterior chamber may cause blurred vision but 
is usually self-limiting [103-105].
Uveitis is a serious condition resulting in severe visual impairment and even blind-
ness if not treated promptly and adequately. In South Africa, referral from lower levels 
of healthcare to a regional ophthalmology unit for further management and initiation 
of (empirical) treatment is indicated. However, even at these units, treatment outcomes 
may be poor due to the low predictive value of the patient’s history and clinical charac-
teristics for aetiology of uveitis. Anterior chamber paracentesis, aspiration and analysis 
of AH will provide a valuable diagnostic procedure that optimizes treatment and sub-
sequent prognosis at a very limited risk. This procedure can be performed in most 
clinical settings, because a well-trained ophthalmic nurse could safely perform anterior 
chamber paracentesis in situations when qualified ophthalmologists are not available. 
Paracentesis is easier to perform than cataract surgery for which ophthalmic nurses are 
trained in some African countries (e.g. Malawi) in the absence of ophthalmologists [106]. 
In addition to skills development, strengthening laboratory infrastructure is warranted. 
Validation of existing diagnostic assays and provision of other resources required to 
analyse aqueous humour for the most common uveitogenic pathogens should be con-
sidered across South Africa. Furthermore, logistic systems, e.g. cold sample transport 
chain, would require optimisation to ensure short turnaround time and maximum clini-
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cal impact of this diagnostic test. Providing such diagnostic service will be cost-effective 
due to reduction of unnecessary use of expensive antimicrobial drugs and aversion of 
blindness and associated socioeconomic costs [107].
Collectively, increased awareness about the unmet need for valuable diagnostic plat-
forms for uveitis is needed. Moreover, discussion among healthcare providers about the 
introduction thereof in routine work-up of uveitis patients in South Africa is highly war-
ranted. Ultimately, these efforts should result in the development of clinical guidelines 
and a training program that includes combined clinical and laboratory evaluation for 
infectious aetiology, including AH sampling to detect the triggering pathogen, chest 
X-ray and sputum evaluation for M. tuberculosis and serological evaluation for syphilis.
OculAr cOnDItIOnS ASSOcIAtED WItH HIV InfEctIOn AnD Art
Currently there is no cure for HIV, but the mass introduction of ART has resulted in pro-
longed survival even to a normal life expectancy in high-resource countries [108-109]. 
In Western countries, the introduction of ART resulted in a substantial reduction in in-
fectious ocular conditions associated with severe immunodeficiency, but data from the 
African continent are largely unavailable [18-19, 21]. In South Africa, especially in rural 
settings, ART coverage is still low and individuals still present to healthcare facilities for 
the first time with moderate to severe immunodeficiency. New strategies to achieve HIV 
epidemic control, such as the Joint United Nations Programme on HIV/AIDS (UNAIDS) 
90-90-90 campaign, aim to diagnose 90% of all HIV-infected individuals, provide ART for 
90% of those diagnosed with HIV infection and achieve undetectable HIV viral loads for 
90% of those on treatment by the year 2020 [110]. These efforts will most likely result 
in decreasing numbers of HIV-infected individuals with severe immunodeficiency and 
possibly in a decrease in the incidence of infectious ocular conditions as observed in 
Western countries [18-19]. However, available data from Western countries also suggest 
that metabolic and vascular changes associated with extended use of ART may affect 
the eye, manifesting for example as retinopathy [18]. Also, accelerated ageing and frailty 
among HIV-infected individuals on ART may also affect ocular structures such as the 
lens [21]. Finally, persistent immune activation in individuals on ART could predispose 
to ocular conditions like age-related macular degeneration [111]. ART is lifelong, but 
long-term effects of ART and chronic HIV infection on the prevalence of ocular disease 
are largely unknown, especially from sub-Saharan African settings with high HIV preva-
lence. Such impact, may greatly affect HIV-infected individuals’ quality of life [3]. As the 
number of HIV-infected individuals on ART will increase, it is crucial to obtain insight in 
the distribution of ocular disease and manifestations among HIV-infected individuals 
with and without ART in rural South Africa to identify preventive measures.
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In this thesis, we described a retrospective cohort study where we recruited four 
groups of adult individuals: (1) individuals without HIV infection (n=105), (2) HIV-
infected individuals naïve for ART (n=16), (3) HIV-infected individuals on ART for <12 
months (defined as short-term ART) (n=56) and (4) HIV-infected individuals on ART for 
>36 months (defined as long-term ART) (n=165) (chapter 7). We showed that ocular 
disease is more common among HIV-infected individuals, especially those on long-term 
ART, and causes substantial morbidity in our setting.
Eye complaints were significantly more often reported by HIV-infected participants 
than those without HIV infection (chapter 7). Moreover, the external eye and anterior 
segment were more often affected among HIV-infected than uninfected individuals, 
with blepharitis, pterygium, keratoconjunctivitis sicca and cataract formation were the 
main conditions in our HIV-infected population. Limited data on the mechanisms that 
lead to non-infectious ocular conditions among HIV-infected individuals are available, 
but several mechanisms may be involved. First, HIV-induced immunosuppression may 
lead to a reduced ability to control normal flora and to changes in cutaneous glands of 
the eyelids resulting in blepharitis [112-113]. Second, HIV-mediated immune activation 
and lymphocytic infiltration may cause destruction of lacrimal glands and damage the 
conjunctiva, which might play a role in the development of keratoconjunctivitis sicca 
and pterygium formation [113-114]. Finally, accelerated senescence due to HIV infection 
may result in accelerated formation of cataract [21]. The posterior segment, especially 
HIV-retinopathy, was more often affected among HIV-infected individuals on ART for 
long-term than those on short-term ART (chapter 7). Moreover, HIV-retinopathy was 
associated with ART use for longer period of time. These observations are surprising as 
available data from Western countries observed a decrease in frequency of HIV-retinop-
athy among HIV-infected individuals on ART compared to those who were ART-naïve, 
suggesting that ART decreases the risk of HIV-retinopathy [18]. In our study, a trend for 
low nadir CD4 cell count of <50 cells/mm³ and the occurrence of HIV retinopathy was 
observed, which could in part explain the high frequency of HIV-retinopathy observed 
in our study as nadir CD4 cell count was generally low, especially among participants 
on long-term ART. In line with our observations, lower nadir CD4 cell count and more 
prolonged ART use have been associated as risk factors for non-infectious HIV related 
conditions such as cardiovascular disease or diabetes mellitus in other studies [115-116]. 
This suggests that the nadir CD4 cell count is likely to be an important risk factor of 
non-infectious ocular conditions and stresses the importance of the UNAIDS 90-90-90 
campaign [110]. In line with HIV-retinopathy, clinical detectable cataract was also associ-
ated with long-term ART use in our study (chapter 7). This finding is in line with a Danish 
nationwide population-based cohort study that reported introduction of ART as a risk 
factor for cataract and cataract surgery [117]. The increased risk for cataract surgery 
observed in this Danish study is of great importance as it suggests that participants 
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on ART in our population are at high risk of developing cataract that requires surgi-
cal management over time [117]. This would have major consequences for the South 
African healthcare system, as the cataract surgical rate in South Africa is already low and 
the number of individuals on ART will only increase [118].
In conclusion, HIV-infected individuals, even after ART initiation and especially those 
on long-term ART, are at risk of developing ocular disease compared to HIV-uninfected 
individuals. As such, these individuals are at risk of suffering from ocular morbidity, 
including visual disability. Increased awareness among healthcare providers working 
in the HIV/ART programmes for symptoms and early clinical signs of ocular disease in 
order to initiate prompt treatment or referral to the relevant level of care is therefore 
of paramount importance. Furthermore, implementation of a regular ophthalmologic 
screening programme for HIV-infected individuals is warranted to prevent ocular mor-
bidity and possible future visual impairment.
futurE PErSPEctIVES
In this thesis, we described that HIV-infected individuals are at risk of developing two 
important infectious ocular conditions namely keratitis and uveitis and that even after 
ART initiations, non-infectious ocular conditions remain common. In our high HIV preva-
lence setting, viral keratitis and uveitis were mainly caused by HHVs. Additionally, mixed 
infection in viral keratitis due to an infection with a bacterial pathogen, is prominent for 
infectious keratitis. Viral aetiology of these ocular conditions is more common among 
HIV-infected individuals who are at increased risk for developing ocular infections with 
poorer visual outcome compared to HIV-uninfected individuals. In our setting, VZV is 
the predominant aetiological pathogen in both keratitis and uveitis, which is in contrast 
to available studies from high-resource settings [28, 66]. Additionally, ocular TB and to a 
lesser extent ocular syphilis play an important role in uveitis patients in our setting. As 
such, infectious ocular disease are a major healthcare challenge in our setting. Available 
data on ocular disease, which predominantly come from high-resource settings from 
Western countries, cannot be extrapolated to a rural, low-resource and high HIV preva-
lence setting in South Africa. Development of “tailor-made” clinical guidelines for eye 
care in sub-Saharan Africa, including South Africa, is therefore of paramount importance 
to improve clinical management and prevent visual impairment. Current management 
of ocular infectious conditions, especially infectious keratitis and uveitis, commonly 
leads to misdiagnosis, under-treatment and preventable visual impairment. Therefore, 
these “tailor-made” clinical guidelines for eye care should include laboratory analysis of 
corneal swabs in case of infectious keratitis and aqueous humour in case of uveitis to 
support presumed diagnosis. This thesis seeks to draw attention to the unmet need for 
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these valuable diagnostic analyses and to encourage discussion among healthcare pro-
viders about the introduction thereof in routine work-up of patients with these ocular 
conditions in rural South Africa.
Apart from infectious keratitis and uveitis, non-infectious ocular conditions remain 
common among HIV-infected individuals after ART initiation which warrants the need 
for regular routine ophthalmological screening for ocular disease among HIV-infected 
individuals. However, currently eye care is not incorporated in existing clinical guidelines 
for HIV-infected individuals in the (pre)ART program of South Africa. As such, eye care 
should become part of standard clinical care for HIV-infected individuals in the (pre)ART 
program and development of regular routine ophthalmological screening guidelines is 
highly needed. Also, increased awareness among healthcare providers in the field of HIV 
in rural South Africa is highly warranted for early recognition, diagnosis and initiation of 
treatment or prompt referral to the adequate level of care.
Theoretically, today’s eye care in South Africa should be provided at all healthcare 
levels with primary eye care, rendered by professional, non-ophthalmic or ophthalmic 
and rural healthcare providers, as its cornerstone [119]. However, during the course 
of our studies we observed a significant delay in presentation to hospitals suggesting 
that eye care receives limited attention in PHC facilities in rural settings. Although oph-
thalmic nurses are trained in these settings, their deployment to provide eye care and 
ophthalmological screening after completion of their training is limited and in practice 
they predominantly work as general nurses covering all clinical fields. Moreover, oph-
thalmologists are unavailable since they are concentrated in urban areas only, leaving 
rural communities devoid of the highest quality of eye care professionals [120]. As a 
result, individuals in rural settings are at increased risk of suffering from ocular morbid-
ity. Eye care therefore needs to be prioritized at local and national health level in South 
Africa. Effective eye care depends on many factors including the availability of budget, 
essential resources and drugs, human resources and referral and mobility options as 
most important. Lack of ophthalmological expertise and skills, essential resources, oph-
thalmic drugs and referral systems are major challenges in rural settings. This stresses 
the need for further studies to obtain insight in determinants, barriers and challenges 
of ophthalmology services in South Africa in order to provide urgent in-depth health 
system strengthening that will improve eye care and reduce preventable visual impair-
ment.
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Oogziekten vormen een belangrijk, wereldwijd gezondheidsprobleem. Wanneer ze 
leiden tot slechtziendheid of blindheid heeft dat grote gevolgen voor de kwaliteit van 
leven van mensen die er door getroffen worden. Het vóórkomen van slechtziendheid en 
blindheid is ongelijk verdeeld over de wereld: ongeveer 90% van alle slechtzienden leeft 
in een ontwikkelingsland. Op het Afrikaanse continent wordt dit mede veroorzaakt door 
de hoge prevalentie van het humaan immunodeficiëntievirus type 1 (HIV). Doordat dit 
virus specifieke cellen van het immuunsysteem aantast, neemt de weerstand van de 
patiënt tegen infecties af. Micro-organismen krijgen daardoor de kans om de ogen te 
infecteren, wat op den duur tot blindheid kan leiden. Alleen al in Zuid-Afrika zijn 6.8 
miljoen mensen besmet met HIV. Er zijn helaas geen goede gegevens beschikbaar over 
de meest voorkomende oogziekten in Afrika, inclusief Zuid-Afrika. Beter inzicht hierin is 
van essentieel belang om de huidige oogheelkundige zorg in deze regio te verbeteren 
en effectievere oogheelkundige preventieprogramma’s te ontwikkelen, waardoor blind-
heid voorkomen kan worden.
Dit proefschrift beschrijft onderzoek naar het vóórkomen van infectieuze en niet-
infectieuze oogziekten in een ruraal gebied in Zuid-Afrika met een hoge HIV-prevalentie. 
Alle studies in dit proefschrift zijn uitgevoerd in het district Mopani in de provincie 
Limpopo. De gezondheidszorg in dit district heeft prioriteit binnen de Zuid-Afrikaanse 
regering vanwege de huidige slechte kwaliteit, de grote armoede onder de bevolking, 
de hoge graad van analfabetisme en werkloosheid en de zeer hoge prevalentie van HIV 
in dit gebied.
Allereerst werd de seroprevalentie bestudeerd van humane herpesvirussen (HHV) in 
Mopani. Van de in totaal acht bekende HHV zijn het herpes simplex virus type 1 (HSV-1), 
het varicella-zoster virus (VZV) en het cytomegalovirus (CMV) de belangrijkste veroor-
zakers van ooginfecties. Wereldwijd komen deze virussen veel voor. Gegevens over het 
Afrikaanse continent zijn echter schaars. Omdat de seroprevalentie van HHV verschilt 
per regio, kunnen infectiegegevens uit het ene land niet zomaar worden overgenomen 
voor het andere land. Kenmerkend voor HHV is de eigenschap dat deze virussen na 
primaire infectie latent aanwezig blijven in het lichaam, veelal zonder waarneembare 
schade aan te richten. Als gevolg van een afname van de weerstand kunnen ze echter 
na verloop van tijd weer actief worden. Deze reactivatie gaat doorgaans gepaard met 
ernstige ziekteverschijnselen waaronder ooginfecties. Vanwege de verminderde functie 
van hun immuunsysteem hebben HIV-geïnfecteerde personen een verhoogde kans op 
reactivatie van HHV. Onderzoek hiernaar is voornamelijk in westerse landen uitgevoerd. 
Daaruit blijkt dat CMV een grote rol speelt: toen er nog geen behandeling mogelijk 
was tegen HIV, kreeg ongeveer 40% van alle HIV-dragers te kampen met CMV-retinitis, 
een infectie van het netvlies die leidt tot blindheid. De introductie van antiretrovirale 
middelen tegen HIV heeft in de geïndustrialiseerde wereld geleid tot het vrijwel geheel 
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verdwijnen van deze ooginfectie bij deze groep patiënten. Dergelijke gegevens over de 
situatie in Afrika ontbreken vrijwel volledig, ondanks het feit dat dit continent het hardst 
getroffen is door de HIV-epidemie. Daarom werd in ons onderzoeksgebied allereerst 
gestart met het vaststellen van de seroprevalentie van HSV-1, HSV-2, VZV, CMV en het 
Epstein-Barr virus (EBV) in een groep van HIV-geïnfecteerde personen. In hoofdstuk 2 
laten wij zien dat de seroprevalentie van deze virussen in Mopani zeer hoog is: 98% voor 
HSV-1, 87% voor HSV-2, 89% voor VZV en 100% voor EBV en CMV. Ondanks deze zeer 
hoge besmettingsgraad wordt er in de zorg voor HIV patiënten in Zuid-Afrika vrijwel 
geen aandacht besteed aan deze virale infecties. Omdat HIV-geïnfecteerde personen 
een verhoogd risico lopen op het ontwikkelen van HHV-gerelateerde ziekten is het 
belangrijk dat deze mensen en hun zorgverleners zich daarvan beter bewust worden. 
Als de symptomen in een vroeg stadium herkend worden, zal er eerder hulp worden 
gezocht en kan er tijdig met behandelen worden gestart. Dit laatste is vooral belangrijk 
omdat vroegtijdige behandeling in de meeste gevallen blindheid kan voorkomen. Daar-
naast spelen HHV (met name HSV-2) ook een rol in de verspreiding van HIV. Interven-
tiestrategieën om bijvoorbeeld HSV-2 gerelateerde overdracht van HIV te verminderen, 
zouden dan ook een grotere aandacht moeten krijgen binnen het HIV-programma in 
Zuid-Afrika.
In hoofdstuk 3 wordt onderzoek beschreven naar het vóórkomen en het klinisch beeld 
van infectieuze keratitis (infectie van het hoornvlies) in Mopani. Deze aandoening is een 
belangrijke veroorzaker van blindheid. Infectieuze keratitis kan veroorzaakt worden 
door zowel virussen, bacteriën alsook schimmels. Hoewel HIV-dragers een verhoogd 
risico hebben op virale keratitis, richten de huidige klinische richtlijnen in Zuid-Afrika 
zich voornamelijk op bacteriële verwekkers. Dit heeft tot gevolg dat mensen die zich 
bij rurale klinieken en ziekenhuizen melden met verschijnselen van een infectieuze 
keratitis op dit moment uitsluitend worden behandeld met antibiotica. Uit ons onder-
zoek blijkt echter dat HHV (voornamelijk VZV) in Mopani belangrijke veroorzakers van 
deze aandoening zijn, al dan niet gecompliceerd door secundaire bacteriële infecties. 
Dit is nog niet eerder beschreven en vooral belangrijk omdat de behandeling van een 
infectieuze keratitis bepaald wordt door de aard van de verwekker. De huidige richtlijn 
die uitsluitend antibacteriële middelen voorschrijft, is dus niet afdoende en leidt tot on-
derbehandeling. Anders dan in westerse landen waar HSV-1 de belangrijkste verwekker 
is van infectieuze keratitis, geldt voor de populatie in Mopani dat VZV de meest voor-
komende oorzaak is. Hoogstwaarschijnlijk speelt de hoge HIV-prevalentie in dit gebied 
hierbij een belangrijke rol, omdat HIV-geïnfecteerde personen een sterk verhoogd risico 
hebben op het ontwikkelen van VZV-gerelateerde ziekten. Dit verhoogde risico is veel 
minder duidelijk aanwezig voor HSV-1. In hoofdstuk 3 wordt de belangrijke rol bespro-
ken van de polymerasekettingreactie (PCR) en het kweken van bacteriën en schimmels 
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uitgevoerd op hoornvliesuitstrijkjes. Een PCR-analyse geeft voornamelijk informatie 
wanneer de ontsteking zich in het buitenste laagje van het hoornvlies (epitheel) bevindt. 
Bij ontstekingen dieper in het hoornvlies is de toegevoegde waarde van PCR-analyse 
minder groot. In ongeveer de helft van alle virale keratitiden werd ook een bacteriële su-
perinfectie aangetroffen. Hoewel dit niet met een slechtere prognose was geassocieerd, 
is het aannemelijk dat dergelijke keratitiden wel gebaat zijn bij zowel een antibacteriële 
alsook een antivirale therapie. Naast de juiste keuze is ook het vroegtijdig behandelen 
van een infectieuze keratitis van groot belang om complicaties te voorkomen. Dit werd 
bevestigd in onze studie: naarmate de patiënten langer wachtten voordat ze naar de 
kliniek kwamen, nam de ernst van de slechtziendheid toe. Dit benadrukt het belang 
van snelle en adequate behandeling van patiënten met een infectieuze keratitis. Omdat 
de meeste patiënten in de bestudeerde populatie zich in eerste instantie wenden tot 
klinieken in de eerstelijns gezondheidszorg, is het van groot belang dat antivirale the-
rapie voor infectieuze keratitis ook beschikbaar komt binnen de basisgezondheidszorg 
in ruraal Zuid-Afrika.
Hoofdstuk 4 beschrijft de oogheelkundige complicaties bij herpes zoster ophthalmicus 
(HZO). Dit is de klinische manifestatie die op kan treden na reactivatie van een latente 
VZV-infectie in de vijfde hersenzenuw (de nervus trigeminus). Een dergelijk reactie be-
gint met huidveranderingen in het gelaat, die gevolgd kunnen worden door oogproble-
men. Het onderzoek toont aan dat het spectrum van de oogheelkundige complicaties 
van HZO divers is en dat de complicaties die leiden tot blindheid veel vóórkomen in de 
onderzochte populatie. Net als voor infectieuze keratitis geldt voor HZO dat de ernst van 
de aandoening sterk bepaald wordt door de tijd die verstreken is voordat de patiënt de 
juiste medische zorg krijgt. Wanneer binnen 72 uur na het ontstaan van de huidafwij-
kingen gestart wordt met behandeling kunnen oogcomplicaties worden voorkomen. 
Dit onderstreept opnieuw de noodzaak om antivirale therapie beschikbaar te stellen 
voor de eerstelijns gezondheidszorg in ruraal Zuid-Afrika. Geen specifieke redenen voor 
het (te) laat zoeken van medische hulp werden gevonden. Het is echter duidelijk dat 
er voor deze patiënten veel winst valt te behalen wanneer het ziektebeeld van HZO 
vroegtijdig wordt herkend door de zorgverleners maar vooral ook door de patiënten 
zelf. Goede voorlichting over de risico’s van ooginfecties bij HIV-dragers kan daartoe 
bijdragen. Daarnaast geldt ook het omgekeerde: wanneer patiënten met HZO worden 
aangetroffen, dient de zorgverlener bedacht te zijn op een onderliggende HIV-infectie.
In hoofdstuk 5 en 6 wordt het klinisch beeld en de etiologie van uveïtis beschreven, een 
potentieel agressief ziektebeeld dat een veel voorkomende oorzaak is van blindheid in 
ontwikkelingslanden. Uveïtis kan zowel infectieus van aard zijn als niet-infectieus (bij-
voorbeeld veroorzaakt door een auto-immuunaandoening). Hoewel de hoge HIV-pre-
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valentie in Zuid-Afrika waarschijnlijk de kans op het krijgen van een infectieuze uveïtis 
vergroot, is er nog maar weinig bekend over de oorzaken van uveïtis in deze regio. Een 
dergelijk inzicht is van groot belang omdat adequate behandeling van uveïtis bepalend 
is voor de prognose. In hoofdstuk 5 wordt onderzoek beschreven naar de oorzaken van 
uveïtis in onze onderzoekspopulatie en wordt aangetoond dat de infectieuze vorm van 
uveïtis de belangrijkste vorm van uveïtis is met HHV, Mycobacterium tuberculosis (de ver-
oorzaker van tuberculose) en Treponema pallidum (de veroorzaker van syfilis) als belang-
rijkste verwekkers. HHV-gerelateerde uveïtis werd voornamelijk veroorzaakt door VZV. 
Onze bevindingen wijken daarmee af van de beschikbare gegevens uit westerse landen, 
waar CMV de belangrijkste verwekker is van uveïtis bij HIV-geïnfecteerde personen. Dit 
onderstreept het belang van regio-specifieke klinische richtlijnen voor uveïtis. Naast 
HHV als veroorzaker van uveïtis is er een belangrijke rol weggelegd voor M. tuberculosis. 
Dit is zeer relevant omdat er momenteel in Zuid-Afrika geen aandacht wordt besteed 
aan M. tuberculosis als verwekker van deze aandoening. Zo bevat de Zuid-Afrikaanse 
tuberculoserichtlijn geen informatie over de oogheelkundige ziekteverschijnselen bij 
tuberculose en wordt er niets geschreven over de noodzakelijke oogheelkundige zorg.
De diagnostiek van uveïtis vormt een groot probleem in ontwikkelingslanden. Hoewel 
een snelle diagnose en snelle start van specifieke therapie van groot belang zijn om 
blindheid te voorkomen, is dit hier veelal niet haalbaar. Dit komt onder meer door het 
gebrek aan oogheelkundige expertise, waardoor diagnose op basis van klinische ver-
schijnselen vrijwel volledig ontbreekt. In hoofdstuk 5 wordt aangetoond dat de huidige 
diagnostiek van uveïtis in Zuid-Afrika kan worden verbeterd door deze uit te breiden 
met laboratoriumdiagnostiek van het voorste oogkamervocht (in verband met HHV) en 
een thoraxfoto (in verband met tuberculose).
In hoofdstuk 6 wordt een casus van een infectieuze uveïtis beschreven, die wordt 
veroorzaakt door M. tuberculosis bij een HIV-geïnfecteerde patiënt vlak na het starten 
van de behandeling met antiretrovirale medicijnen. Dit ziektebeeld was hoogstwaar-
schijnlijk onderdeel van een zogenaamd “immune reconstitution inflammatory syn-
drome”, een syndroom dat kan optreden als gevolg van een (gedeeltelijk) herstel van de 
immuunfunctie na succesvolle behandeling met antiretrovirale medicijnen. Deze casus 
benadrukt het belang van screening op (oculaire) tuberculose en basaal oogheelkundig 
onderzoek in 2 fases van behandeling met antivirale middelen: voordat gestart wordt 
met medicatie en tijdens routinematige vervolgbezoeken.
In hoofdstuk 7 wordt het effect beschreven van de antiretrovirale therapie op het 
vóórkomen van oogziekten in Mopani. Vanaf het moment dat medicamenteuze behan-
deling met antiretrovirale medicijnen voor HIV mogelijk werd, is de levensverwachting 
van HIV-geïnfecteerden sterk verbeterd. In westerse landen werd tevens een daling 
van het aantal ooginfecties gezien, voornamelijk als gevolg van de verbetering van de 
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immuunstatus dankzij deze medicijnen. De invloed van deze middelen in Afrikaanse 
landen op het vóórkomen van oogziekten is echter onbekend. In Zuid-Afrika is de 
dekkingsgraad van antiretrovirale medicijnen nog altijd laag. Daarnaast zoeken HIV-
geïnfecteerden vaak pas in een laat stadium van de ziekte medische hulp, waardoor 
het immuunsysteem inmiddels al ernstig is aangetast. Nieuwe strategieën van zowel de 
Zuid-Afrikaanse overheid en organisaties als Joint United Nations Programme on HIV/
AIDS (UNAIDS) zullen hopelijk leiden tot een afname van het aantal patiënten met een 
ernstige immuundeficiëntie en daarmee wellicht ook tot een afname van het aantal 
infectieuze oogziekten. Aangezien deze medicijnen levenslang ingenomen moeten 
worden, zijn de effecten op het vóórkomen van oogziekten echter nog grotendeels 
ongewis. Enkele studies uit westerse landen (onder andere in de Verenigde Staten van 
Amerika en Italië) rapporteren dat mensen die antiretrovirale medicijnen gebruiken een 
verhoogd risico hebben op niet-infectieuze oogziekten zoals diverse vormen van reti-
nopathie en staar. In hoofdstuk 7 wordt de verdeling en manifestatie beschreven van 
oogziekten bij HIV-geïnfecteerde personen in Mopani die wel of niet antiretrovirale me-
dicijnen gebruikten. In deze studie tonen wij aan dat oogklachten en oogziekten meer 
voorkomen bij HIV-geïnfecteerden dan bij niet HIV-geïnfecteerde personen, waarbij het 
voornamelijk gaat om uitwendige oogziekten (vooral ontsteking van de ooglidrand) en 
ziekten van het voorste segment van het oog (vooral pterygium, droge ogen en staar). 
Daarnaast kwamen er bij HIV-geïnfecteerde personen die langer dan drie jaar antire-
trovirale medicijnen gebruikten meer oogziekten voor van het achterste oogsegment 
(vooral HIV-geassocieerde retinopathie) dan bij personen die deze medicijnen minder 
dan één jaar gebruikten. Een HIV-geassocieerde retinopathie is zowel geassocieerd met 
de duur van het gebruik van deze medicatie als met de mate waarin het immuunsys-
teem is aangetast bij de start van deze therapie. Ook staar komt in Mopani meer voor 
bij personen die langer dan drie jaar antiretrovirale medicijnen gebruikten en de kans 
om staar te krijgen nam toe bij toename van de periode waarin deze medicatie werd 
gebruikt.
Verschillende mechanismen kunnen bijdragen aan de verhoogde kans op oogziekten 
bij HIV-geïnfecteerde personen. Zo lijkt bijvoorbeeld de status van het immuunsysteem 
bij de aanvang van de behandeling met antiretrovirale medicijnen een rol te spelen. 
Hierop kunnen HIV programma’s inspelen door een vroegtijdige start met deze medi-
cijnen te bevorderen. In het huidige HIV-programma van Zuid-Afrika wordt nauwelijks 
aandacht aan oogziekten geschonken. De resultaten van ons onderzoek laten zien dat 
oogziekten veel vóórkomen in de onderzochte bevolkingsgroep. Wanneer zorgverle-
ners in Zuid-Afrika zich hier meer van bewust worden, zal dit zeker bijdragen aan het 
tijdig onderkennen van de symptomen waardoor sneller met behandelen kan worden 
begonnen. Daarnaast zou ontwikkeling en implementatie van reguliere oogheelkun-
dige screeningsprogramma’s voor HIV-geïnfecteerde personen – ook na het starten van 
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antiretrovirale therapie – kunnen bijdragen aan het vroegtijdig opsporen van oogziek-
ten, waardoor behandeling tijdig kan worden ingezet.
Samenvattend heeft onderzoek beschreven in dit proefschrift geleid tot nieuwe inzich-
ten in de oorzaken en verschijningsvormen van oogziekten bij mensen die met HIV zijn 
geïnfecteerd in een Afrikaans gebied met een zeer hoge HIV-prevalentie. Deze inzichten 
wijken op bepaalde gebieden af van het bestaande beeld dat voornamelijk gebaseerd is 
op westerse studies en zijn daar een belangrijke aanvulling op. Het onderzoek laat zien 
dat er dringend nieuwe klinische richtlijnen en preventiestrategieën moeten worden 
ingevoerd in Zuid-Afrika, die gericht zijn op het vroegtijdig opsporen en behandelen 
van oogziekten bij mensen die met HIV zijn geïnfecteerd.
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“The journey is the destination.” Dan Eldon.
Mijn journey is gevormd door alle inspirerende mensen die ik heb ontmoet en met wie 
ik de afgelopen vier jaar heb mogen samenwerken. Hen allen wil ik enorm bedanken.
Allereerst gaat mijn dank uit naar al mijn patiënten en hun naasten voor hun medewer-
king aan mijn studies. Dankzij hen is dit proefschrift tot stand gekomen waarmee we de 
challenges van Mopani op de kaart hebben gezet. “I know a change is gonna come, oh 
yes it will.” Earl Simmons (DMX).
“Daar heb je die Schaftenaar weer…”. Ab Osterhaus.
Beste Ab, na een kleine omweg kwam ik met een projectvoorstel bij je in Rotterdam 
terecht. Vanaf dat moment heb ik onze samenwerking als prettig ervaren. Al was het op 
afstand, je was altijd goed te bereiken voor mijn vragen. Ik wil je hartelijk bedanken voor 
de mogelijkheid die je me hebt gegeven mijn promotieonderzoek uit te kunnen voeren 
in Zuid-Afrika.
“One paper a day keeps the promotor away”. Georges Verjans.
georges, bedankt voor de sturing, suggesties en adviezen. Je commentaar op 
manuscripten leidde altijd tot een verbetering en een significant heldere boodschap.
“Stress is een keuze”. Remco Peters.
remco, waar begin ik… Het was in 2011 dat ik samen met Tanja bij jou, femke en Stijn 
op bezoek kwam om na te gaan of een promotietraject in “jouw” setting mogelijk was en 
of we ons als gezin thuis konden voelen in het rurale Zuid-Afrika. Het klikte direct en een 
volle werkweek volgde. In die week hebben we diverse klinieken en ziekenhuizen be-
zocht en hebben we de basis gelegd voor het proefschrift dat hier nu voor je ligt. Jij zag 
en ziet mogelijkheden die andere niet zagen en zien. De meest levendige herinnering 
aan die week is uiteraard onze meeting in het Dr. C.N. Phatudi Hospital, waar de auto-
banden in brand stonden en de bakstenen over ons hoofd vlogen. Het schrikte ons niet 
af. Die ene week in 2011 heeft mijn leven op een zeer positieve manier veranderd, dank 
daarvoor. Naast die eerste week hebben we ongelofelijk veel meegemaakt, je zou er 
een thesis van kunnen schrijven: whisky, vleermuizen, koffieperikelen, METc aanvragen, 
Mankweng, klimgordels, …, etc. Je bent daarnaast één van de weinige die de volgende 
stelling echt begrijpt: “Mopani? Never a dull moment!”. Ook de momenten buiten werk, 
samen met onze families, zijn zeer waardevol. Een whiskyfles hoort in een avond leeg te 
gaan! Je bent een prettige promotor geweest en je blijft, naast een collega, een vriend. 
Onze samenwerking zal zeker een vervolg hebben. Dus: tot snel in Zuid-Afrika.
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“En wat was de CD4 count?”. Ina Meenken.
Ina, eigenlijk begint alles, via de werkgroep tropische oogheelkunde, bij jou. Ik kwam bij 
jou met een zeer open vraag: ik wil promoveren in Afrika op het onderwerp infectieuze 
oogziekten. Je hebt me altijd gesteund, verdedigd en geholpen. Jij bracht mij in contact 
met Remco en bent altijd aan boord gebleven, ook al ging het project uiteindelijk naar 
Rotterdam. Je input is altijd van grote waarde geweest.
“Tot ziens!”. Seerp Baarsma.
Seerp, eerst vanuit het ROI, samen met netty Dorrestijn, ondersteunde je mijn projec-
ten, later vooral in de rol als expert opinion en medeauteur. Je commentaar op klinische 
vragen is gewoonweg fantastisch: geen woord teveel en glashelder. Je bezoek, samen 
met Jan Pameijer, was meer dan waardevol. Het was een gezellige week waarbij de 
ondersteuning en waardering die ik van jullie kreeg geweldig was. De verhalen over 
vroeger en hoe alles anders was, zullen me nog lang bijblijven.
Jan van meurs en Dion Paridaens, graag wil ik jullie bedanken voor de mogelijkheid 
die jullie me hebben gegeven mijn promotieonderzoek te verrichten in Zuid-Afrika. Op 
mijn sollicitatiegesprek kwam ik met veel plannen en ideeën die stuk voor stuk, mede 
door de ondersteuning vanuit Het Oogziekenhuis Rotterdam, uitgevoerd zijn.
Graag wil ik ook de (ex-)leden van de Herpesgroep Rotterdam bedanken. In 2011 kwam 
ik na een hectisch jaar Chirurgie ineens te werken op een laboratorium. Dat was een 
immens verschil waarbij jullie, monique, Werner, gijs, freek, met jullie humor hebben 
bijgedragen aan een fijne tijd. Daarnaast wil ik graag het secretariaat van de afdeling 
bedanken, in het bijzonder Simone en loubna, voor de geweldige hulp die jullie me 
gaven bij vragen vanuit Zuid-Afrika en voor de gezellige gesprekken tijdens het wach-
ten op een vrij plekje in Ab’s overvolle agenda. Beste Wim en Avinash, dank voor jullie 
geduld en uitleg bij alle financiële aspecten.
“E bitswa Africa, Go nna ke gae! (They call it Africa, I call it home!)”. Author unknown.
Al my projects have been conducted in the beautiful country South Africa. I owe every-
thing to the great people of this country that welcomed me and my family since 2011.
Dear Helen and James, how can I ever thank you and Anova Health Institute enough?! 
The freedom, support, hospitality, and kindness I received as a foreigner is amazing. 
Partnering with you has been a pleasure and I do hope we will continue to work together 
to improve healthcare and especially eye care in South Africa. Jean, from a senior doctor 
to program manager: a big step, but you killed it! It was great to have a leader in Tzaneen 
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again and it was great that this leader was you. The trips to Johannesburg and Durban 
were valuable and our discussions about the history of South Africa, the South African 
healthcare system, the HPCSA, the way forward, and many other topics were inspiring.
“Ntshuxeka, aku na xilo lexinga ta lungha (Relax, nothing is under control)”. Sellina Khosa.
Sellina, mutirhi kuloni, nakulobye, kokwana wanga. Na khensa eka ku tirha hiku ti 
nyiketa na rirhandzu. Eka mbhurisano wa matimu na vumundzuku bya tiko raka nwina 
ro xonga swi ta tshama eka mina. Umu tiyisisi wa leswaku malembe aya vuli nchumu!
babra, we share the passion for the eye. Your enthusiasm and dedication to improve the 
quality of eye care is heart-warming, keep up the good work!
I would like to thank all other employees of Anova Health Institute that I have worked 
with, our journey was epic. Special thanks go to Khutso Kurhula: Dikeledi Arvinah, 
mutasa barry, maluleke christina, Olga Daswa, magdeline Kekana, Kgomotso 
Khoza, Emmanuel maakana, fridah maake, Peter maake, maimele makgoba, Siyani 
marima, Vincent matome, ntemby mbambazela, Eddy miyeni, Pinky mnetwa, Au-
brey moagi, mokgadi moagi, moshape Isaac modiba, raymond mohale, mmathabo 
mosue, nathaniel muditambi, mary muhlari, lighty mushwanaa, nkateko nkuna, 
mathilda ralephenya, lucy ranoto, Sylvester rasekgotoma, godfrey Sekgololo, 
buhle Sibuyi and Queen Xivambu. Jarieke, dank voor je gezelligheid in de laatste 
maanden van mijn verblijf in Zuid-Afrika. Het was gezellig en goed dat ik “mijn” office en 
mijn challenges (waaronder never ending koffie perikelen) met je kon delen!
In addition to the Khutso Kurhula team I would like to thank the Soweto and Cape 
Wineland Anova teams for their endless patience, approval does not come in one day, 
and their participation in the baseline study. Special thanks go to: nelis grobbelaar, 
theunis Hurter, moyahabo mabitsi, Hanlie myburgh and bongiwe Vilakazi.
Without the Department of Health, none of the studies would have been conducted. 
I would like to thank the entire Department of Health from the Mopani District, in 
particular dr. bogale and dr. marincowitz. The ophthalmology outpatient depart-
ment staff of “my” three hospitals deserve special a thanks: S. letsoalo, K. mahowa, 
m. ngwenya mosima, Jacky makgahlela, Pretty mametsa, becky talani and Angy 
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In every end, there is also a beginning
H
IV Infection and  O
cular D
isease in South Africa
Erik Schaftenaar
The burden of ocular disease in sub-Saharan African countries is disproportionally high, 
especially among HIV-infected individuals. This thesis presents the results of studies that 
provide novel insight into the clinical field of ophthalmology in a high HIV prevalence setting 
in rural South Africa (Mopani District, Limpopo Province). 
This insight opens the door for further improvement of the clinical care for individuals 
affected by HIV-associated ocular diseases.
